 
 
A Randomized, Double -Blind, Placebo - 
Controlled,  Single -Administration,  Dose - 
Escalation Study of Entolimod on 
Immunosenescence in Healthy Geriatric 
Subjects  Receiving  Influenza  Vaccination  
 
 
[STUDY_ID_REMOVED] 
18JUN2020  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  1 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
 
 
A Randomized, Double -Blind, Placebo -Controlled, Single -Administration, Dose -Escalation 
Study  of Entolimod  on Immunosenescence  in Healthy  Geriatric  Subjects  Receiving  Influenza 
Vaccination  
 
 
 
 
 
 
 
 
Principal  Investigator  and 
Regulatory Sponsor:  
 
 
 
Funding  Sponsor:  Robert  Pignolo,  M.D.,  Ph.D.  
Mayo  Clinic  
200 First Street SW 
Rochester,  MN 55905  
 
Genome  Protection,  Inc (GPI) 
Buffalo, NY 14203, USA  
  
 
Study  Product:   
Entolimod (CBLB502)  
 
Protocol  Number:  (IRBe)   
19-004847  
IND Number:  IND 145282  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial version:  14Aug2019 , Version 2.0 
Revised  version:  18JUN2020,  Version  3.0 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  2 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
Table  of Contents  
STUDY  SUMMARY  ................................ ................................ ................................ ................................ ....................  6 
1 INTRODUCTION  ................................ ................................ ................................ ................................ ..............  7 
1.1 BACKGROUND  ................................ ................................ ................................ ................................ ..................  7 
1.2 INVESTIGATIONAL  AGENT  ................................ ................................ ................................ ................................  9 
1.3 PRECLINICAL  DATA ................................ ................................ ................................ ................................ ..........  9 
1.3.1 Entolimod’s  Mechanism  of Action  ................................ ................................ ................................ ..........  9 
1.3.2 Entolimod’s  Pharmacokinetics  ................................ ................................ ................................ ............  10 
1.3.3 Entolimod’s  Toxicology  ................................ ................................ ................................ .......................  11 
1.3.4 Immunosenescence  and Entolimod  ................................ ................................ ................................ ...... 12 
1.4 CLINICAL  DATA  TO DATE ................................ ................................ ................................ ..............................  13 
1.4.1 Overview  of Clinical  Program  ................................ ................................ ................................ ............  13 
1.4.2 Clinical  Studies  in Healthy  Subjects  and Patients  with Cancer ................................ ...........................  13 
1.5 DOSE  RATIONALE  ................................ ................................ ................................ ................................ ..........  19 
1.6 RISKS  AND  BENEFITS  ................................ ................................ ................................ ................................ ..... 19 
1.6.1 Definition  of DLT ................................ ................................ ................................ ................................  19 
2 STUDY  OBJECTIVES  ................................ ................................ ................................ ................................ ... 19 
3 STUDY  DESIGN  ................................ ................................ ................................ ................................ .............  20 
3.1 GENERAL  DESCRIPTION  ................................ ................................ ................................ ................................ . 22 
3.2 NUMBER  OF SUBJECTS  ................................ ................................ ................................ ................................ ... 22 
3.3 DURATION  OF PARTICIPATION  ................................ ................................ ................................ .......................  22 
3.4 PRIMARY  STUDY  ENDPOINTS  ................................ ................................ ................................ .........................  22 
3.5 SECONDARY  STUDY  ENDPOINTS  ................................ ................................ ................................ ....................  22 
3.6 EXPLORATORY  ENDPOINTS  ................................ ................................ ................................ ...........................  23 
3.7 PRIMARY  SAFETY  ENDPOINTS  ................................ ................................ ................................ .......................  23 
3.8 IDENTIFICATION  OF SOURCE  DATA ................................ ................................ ................................ ................  23 
4 SUBJECT  SELECTION  ENROLLMENT  AND  WITHDRAWAL  ................................ ............................  24 
4.1 INCLUSION  CRITERIA  ................................ ................................ ................................ ................................ ..... 24 
4.2 EXCLUSION  CRITERIA  ................................ ................................ ................................ ................................ .... 24 
4.3 SUBJECT  RECRUITMENT , ENROLLMENT  AND  SCREENING  ................................ ................................ ..............  25 
4.4 EARLY  WITHDRAWAL  OF SUBJECTS  ................................ ................................ ................................ ..............  26 
4.4.1 When  and How  to Withdraw  Subjects  ................................ ................................ ................................ . 26 
4.4.2 Data  Collection  and Follow -up for Withdrawn  Subjects  ................................ ................................ ..... 26 
5 STUDY  DRUG  ................................ ................................ ................................ ................................ .................  27 
5.1 DESCRIPTION  ................................ ................................ ................................ ................................ .................  27 
5.2 TREATMENT  REGIMEN  ................................ ................................ ................................ ................................ ... 27 
5.3 METHOD  FOR  ASSIGNING  SUBJECTS  TO TREATMENT  GROUPS  ................................ ................................ ....... 28 
5.4 PREPARATION  AND  ADMINISTRATION  OF STUDY  DRUG ................................ ................................ .................  28 
5.5 SUBJECT  COMPLIANCE  MONITORING  ................................ ................................ ................................ .............  29 
5.6 PRIOR  AND  CONCOMITANT  THERAPY  ................................ ................................ ................................ ............  29 
5.7 PACKAGING  ................................ ................................ ................................ ................................ ...................  29 
5.8 MASKING /BLINDING  OF STUDY  ................................ ................................ ................................ .....................  30 
5.9 RECEIVING , STORAGE , DISPENSING  AND  RETURN  ................................ ................................ ..........................  31 
5.9.1 Receipt  of Drug  Supplies  ................................ ................................ ................................ .....................  31 
5.9.2 Storage  ................................ ................................ ................................ ................................ ................  31 
5.9.3 Dispensing  of Study  Drug  ................................ ................................ ................................ ....................  31 
5.9.4 Return  or Destruction  of Study  Drug  ................................ ................................ ................................ ... 31 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  3 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 6 STUDY  PROCEDURES  ................................ ................................ ................................ ................................ . 31 
6.1 VISIT 1, SCREENING  VISIT (-28 TO -7 DAYS ) ................................ ................................ ................................ ... 32 
6.2 VISIT 2, TREATMENT  VISIT – DAY 0................................ ................................ ................................ ...............  32 
6.3 VISIT 3, SAFETY  FOLLOW -UP –DAY 1 ................................ ................................ ................................ ............  33 
6.4 VISIT 4, SAFETY  FOLLOW -UP –DAY 7 (REMOTE  VISIT ) ................................ ................................ ...................  33 
6.5 VISIT 5, FOLLOW -UP - MONTH  1 ................................ ................................ ................................ ....................  33 
6.6 VISIT 6, FOLLOW -UP – MONTH  2 ................................ ................................ ................................ ....................  34 
6.7 VISIT 7, FOLLOW -UP – MONTH  6 ................................ ................................ ................................ ....................  34 
6.8 VISIT 8, FOLLOW -UP – MONTH  12 ................................ ................................ ................................ ..................  35 
6.9 MONTHLY  PHONE  VISITS  – MONTH  3- MONTH  11 ................................ ................................ ..........................  35 
6.10 EXAMINATIONS  AND  PROCEDURES  ................................ ................................ ................................ ...........  35 
6.11 LABORATORY  ASSESSMENTS  ................................ ................................ ................................ ....................  35 
6.12 MMSE  AND  QUALITY  OF LIFE (QOL) ASSESSMENTS  ................................ ................................ ................  36 
6.13 FRAILTY  ASSESSMENTS  ................................ ................................ ................................ ............................  37 
6.14 SAVE  ASSESSMENTS  ................................ ................................ ................................ ................................  37 
6.15 ADVERSE  EVENTS  ................................ ................................ ................................ ................................ ..... 37 
7 STATISTICAL  PLAN  ................................ ................................ ................................ ................................ ..... 41 
7.1 SAMPLE  SIZE DETERMINATION  ................................ ................................ ................................ ......................  41 
7.2 STATISTICAL  METHODS  ................................ ................................ ................................ ................................ . 41 
7.3 SUBJECT  POPULATION (S) FOR  ANALYSIS  ................................ ................................ ................................ ....... 43 
8 SAFETY  AND  ADVERSE  EVENTS  ................................ ................................ ................................ .............  43 
8.1 DEFINITIONS  ................................ ................................ ................................ ................................ ..................  43 
8.2 REPORTING  OF SERIOUS  ADVERSE  EVENTS  AND  UNANTICIPATED  PROBLEMS  ................................ ...............  46 
8.2.1 Sponsor -Investigator  reporting:  notifying  the Mayo  IRB ................................ ................................ .... 46 
8.2.2 Sponsor -Investigator  reporting:  Notifying  the FDA ................................ ................................ ............  47 
8.3 UNMASKING /UNBLINDING  PROCEDURES  ................................ ................................ ................................ ....... 48 
8.4 STOPPING  RULES  ................................ ................................ ................................ ................................ ...........  48 
8.5 MEDICAL  MONITORING  ................................ ................................ ................................ ................................ . 49 
8.5.1 Internal  Data  and Safety  Monitoring  Board  ................................ ................................ ........................  49 
9 DATA  HANDLING  AND  RECORD  KEEPING  ................................ ................................ ..........................  49 
9.1 CONFIDENTIALITY  ................................ ................................ ................................ ................................ .........  49 
9.2 SOURCE  DOCUMENTS  ................................ ................................ ................................ ................................ .... 50 
9.3 CASE  REPORT  FORMS  ................................ ................................ ................................ ................................ .... 50 
9.4 RECORDS  RETENTION  ................................ ................................ ................................ ................................ .... 51 
10 STUDY  MONITORING,  AUDITING,  AND  INSPECTING  ................................ ................................ ....... 51 
10.1 STUDY  MONITORING  PLAN ................................ ................................ ................................ .......................  51 
10.2 AUDITING  AND  INSPECTING  ................................ ................................ ................................ ......................  52 
11 ETHICAL  CONSIDERATIONS  ................................ ................................ ................................ ....................  52 
12 STUDY  FINANCES  ................................ ................................ ................................ ................................ ........  53 
12.1 FUNDING  SOURCE  ................................ ................................ ................................ ................................ ..... 53 
12.2 CONFLICT  OF INTEREST  ................................ ................................ ................................ ............................  53 
12.3 SUBJECT  STIPENDS  OR PAYMENTS  ................................ ................................ ................................ ............  53 
13 PUBLICATION  PLAN  ................................ ................................ ................................ ................................ ... 53 
14 REFERENCES  ................................ ................................ ................................ ................................ ................  55 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  4 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 LIST  OF ABBREVIATIONS  
 
Ab Antibody  
AE Adverse  Event/Adverse  Experience  
ALC  Absolute  Lymphocyte  Count  
ALT  Alanine  aminotransferase  
ANC  Absolute  Neutrophil  Count  
AST Serum  aspartate  aminotransferase  
AUC  Area  Under  the Curve  
CFR Code  of Federal  Regulations  
Cmax Maximum  plasma  concentration  
CMV  Cytomegalovirus  
COVID -19 Coronavirus  Disease  2019  
CRF Case  Report  Form  
CRTU  Clinical  Trial  Research  Unit 
DSMB  Data  and Safety  Monitoring  Board  
DSMP  Data  and Safety  Monitoring  Plan 
DLTs  Dose  Limiting  Toxicities  
DNA  Deoxyribonucleic  Acid  
FDA  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GBS  Guillain  Barré  syndrome  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HAI Hemagglutination  inhibition  (assay)  
HBsAg  Hepatitis  B surface  Antigen  
HBV  Hepatitis  B Virus  
HCV  Hepatitis  C Virus  
HIV Human  Immunodeficiency  Virus  
IB Investigator’s  Brochure  
IgG Immunoglobulin  G 
IM Intramuscular  
IND Investigational  New  Drug  Application  
IRB Institutional  Review  Board  
kD Kilodalton  
NHP  Non-human  primates  
PCR Polymerase  Chain  Reaction  
PHI Protected  Health  Information  
PI Principal  Investigator  
RNA  Ribonucleic  acid 
SAE Serious  Adverse  Event/Serious  Adverse  Experience  
SARS -CoV-2 Severe  Acute  Respiratory  Syndrome  Coronavirus 2 
SAVE  Sub-hertz  Analysis  of ViscoElasticity  
SOP Standard  Operating  Procedure  
t½ Mean  terminal  elimination  half-live 
Td Tetanus -diphtheria  vaccine  
TEAEs  Treatment -emergent  adverse  events  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  5 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
TLR5  toll-like receptor  5 
TLRs  Tall-like receptors  
Tmax  Time  at which  maximum  plasma  concentration is  observed  
TT Tetanus  toxoid  
UPIRTSO  Unanticipated  Problems  Involving  Risk to Subjects  or Others  
ULN  Upper  Limit  of Normal  
URI Upper  respiratory  infection  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  6 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
 
Study  Summary  
 
Title A Randomized, Double -Blind, Placebo -Controlled, Single - 
Administration, Dose -Escalated Study of Entolimod on 
Immunosenescence  in Healthy  Geriatric  Subjects  Receiving  Influenza 
Vaccination  
Running Title Entolimod (CBLB502)  
Protocol  Number  19-004847  
Phase  Phase  II 
Methodology  Double -blind,  randomized  placebo -controlled  4-arm study  (3 active 
doses and placebo)  
Overall  Study 
Duration  Approximately  1- 1 ½ years  
Subject  Participation 
Duration  12 months  from  study  drug administration  
Single  or Multi -Site Single -Site 
 
Objectives  Primary efficacy objective is to measure  changes of the  anti- A/H1N1, 
anti-A/H3N2, and anti -B influenza virus strains serum circulating 
antibodies  (as assessed  using  hemagglutination  inhibition  (HAI)  assay) 
levels  
Number  of Subjects  100 Subjects  
Diagnosis  and Main 
Inclusion Criteria  Elderly  (age ≥65 years)  men and women  who are medically  stable  and 
eligible to receive Fluzone High -Dose and have not received the flu 
vaccine within the past 90 days  
 
 
Study  Product,  Dose, 
Route, Regimen  This study will involve a  dose-escalated, single  dose administration of 
Entolimod  (CBLB502)  or placebo.  Subjects  will be randomized  to one 
of the 4 arms:  
• Dose  Level  1: 1 μg 
• Dose  Level  2: 3 μg 
• Dose  Level  3: 10 μg 
• Placebo  
The route  of administration  will be intramuscular.  
Duration of 
Administration  Single  dose administration  
Reference  therapy  Placebo -controlled  
Statistical 
Methodology  Linear mixed effects models compare influenza antibody titers 
measured  repeatedly  over time,  with the primary outcome  being  the 4- 
week measurement.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  7 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
1 Introduction  
 
This document  is a protocol for a human research study. This study will be carried out in 
accordance with the applicable United States government regulations and Mayo Clinic research 
policies and procedures.  
 
1.1 Background  
 
Due to immunosenescence related to aging, vaccin ation within the geriatric population is not as 
efficacious as within the general population. Goodwin et al. reported that the influenza vaccine 
had a 17 -53% clinical efficacy in in the elderly while on the other hand displayed 70 -90% 
clinical efficacy in young adults [1]. This is as a result of vaccinations’ inability to produce an 
adequate immune response in older individuals due to age -related changes in both the  
nonspecific (innate) and specific (adaptive) immune response. Weinburger et al. summarizes t he 
changes in vaccine response with age as an increase in the threshold for induction of an antibody 
response to a vaccine. Older individuals often produce insufficient antibody titers required to 
booster critical vaccinations [2]. Henry et al. has shown t hat elderly adults have less de novo 
somatic hypermutations in immunoglobulin variable genes which leads to less adaptability in 
their antibody responses and less potent hemagglutinin epitopes [3]. This inadequate antibody 
response can be life threatening,  particularly more so in the aging population with other  
comorbid diseases. Compromises to their ability to resist the influenza virus, the most common 
cause of pneumonia infections, has led to hospitalizations, lengthened hospital stays and an 
estimated 1 0,000 to 14,000 deaths in the United States during the 2015 -2016 flu season in the 
over 65 -year-old population [4]. 
 
Enhancing the immune response to various stimuli in the geriatric population is imperative due  
to the increase in life  expectancy and the aging population. During 1975 -2015, life  expectancy at 
birth increased from 72.6 to 78.8 years in the U.S. (CDC, National Center for health statistics) 
and data obtained from the social security administration indicates that a man reachi ng age 65 
today can expect to live, on average, until the age of 84.3 and a woman turning age 65 today can 
expect to live, on average, until the age of 86.6.  
 
Multiple methods have attempted to improve vaccine -induced responses in the elderly,  
including: i ncreasing the vaccine antigen dosage, using booster vaccines, changing the route of 
administration (e.g. intradermal), using vector -based vaccines and adjuvants. Entolimod, a novel 
recombinant protein, is a toll -like receptor 5 (TLR5) agonist developed by Cleveland Biolabs,  
Inc (CBLI) for reducing the risk of death following exposure to potentially lethal irradiation [5], 
and by Kadvax Technologies, Inc as an enhancer for anti -addiction therapies. Toll -like receptors 
(TLRs) recognize conserved pathogen asso ciated molecular patterns and play an important role  
in initiating an innate immune response, which in turn is able to lead to the development of an 
adaptive immune response. Entolimod’s engagement of TLR5 has been shown to result in the 
activation of NF -kB, which mobilizes an innate immune response that drives the expression of 
numerous genes, including inhibitors of apoptosis, scavengers of reactive oxygen species, 
modulators of key hematopoietic growth factors including G -CSF and IL -6, and a spectrum of 
protective  or regenerative  cytokines  [5]. Systemic  activation  of TLR5  by entolimod  provides  a 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  8 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 pharmacological advantage over the activation of other TLRs.  Unlike other TLRs, systemic 
activation of TLR5 by entolimod does not induce cytokines d ysregulation ‘(i.e., “cytokine 
storm”)’ that can contribute to immunopathology. Rather, entolimod induces tissue -protective 
factors including anti -inflammatory cytokines (IL -10), antimicrobial factors (L -17, 
S100A8/S100A9) and antimicrobial small peptides [5]. 
 
Limitations of current and developing vaccines can be overcome by increasing the initial or 
boosted antibody titers thereby increasing the antibody titers above the threshold required for 
efficacy. A recently completed study of entolimod alongside the teta nus-diphtheria vaccine (Td) 
with alum (anti -TT and anti -diphtheria) (IND 017372), demonstrated that a single intermuscular 
(IM) injection of entolimod was able to significantly increase levels of anti -tetanus and anti - 
diphtheria antibodies while producing  no significant adverse effects in healthy adults (ages 18 - 
64). Two subjects also reported subjective feelings of increased immunity (e.g decreased  
seasonal allergy symptoms and decreased incidence of upper respiratory infection (URI) and an 
improvement  in their general  well-being.  Data  from  this study  has prompted  further  investigation 
into the effects of entolimod on antibody generation in the geriatric population. Pre -clinical data 
have shown that in male swiss mice, a single week -long treatment with en tolimod is capable of 
having positive long -term effects on their physiological frailty index [7]. 
 
Based on the collective nonclinical and clinical data with entolimod, it is hypothesized that its 
administration in combination with the influenza vaccine wi ll be safe within the geriatric 
population and result in increased circulating influenza -specific antibodies.  
 
Coronavirus  Disease  2019  (COVID -19) Background  
COVID -19 infection -related mortality has a strong dependence on age.  The risk of death in the 
elderly is so high that COVID19 -induced illness can potentially be defined as aging -related 
disease. Hence, therapeutic development of  COVID19 prophylaxis should focus primarily on the 
elderly population. High vulnerability to COVID19 reflects inefficient immune responses of 
older  people to viral infections, a  well-recognized phenomenon named immune senescence [8]. In 
fact, older people have impaired immunization c apabilities requiring the use of increased doses  
of vaccines; furthermore, they commonly have activated latent viruses that stay suppressed in 
younger people, such as hepatitis B (HBV) or cytomegalovirus (CMV). Today, there are no 
approved drugs for revert ing immune senescence and the high vulnerability of older people to 
viral infections, together with their reduced capability to be protected by vaccination, remain 
unmet medical needs.  
 
Broad studies of entolimod’s pharmacological properties and mechanism of action uncovered its 
efficacy as an antiaging drug, including its ability to significantly improve responses of elderly 
mice with immune senescence to different vaccines. These data, together with published results 
on an antiviral effect of TLR5 stimula tion obtained by others, suggest that treatment of elderly 
humans who are at risk of COVID19 infection with entolimod can reduce their risk of infection, 
the severity of illness and even death by reverting their immune senescence and thereby 
improving resi stance to infection.  We intend to generate preliminary data on the use of 
entolimod,  in treating people who are at high -risk of COVID 19 infection and development of 
severe illness.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  9 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 1.2 Investigational  Agent  
 
Entolimod is provided as a sterile, c lear, colorless or slightly yellow liquid for IM injection. The 
drug is supplied in 2 mL Type 1 DIN 2R glass vials secured with V35 bromo -butyl injection 
stoppers and sealed with aluminum white flip off caps. Each single -use vial is prefilled with 50 
µg of  entolimod in 0.5 mL (concentration of 10 µg/100 µL). Entolimod diluent comprises  
sodium chloride (8.0 mg/mL), potassium chloride (0.2 mg/mL), disodium hydrogen phosphate 
dehydrate (1.44 mg/mL), potassium dihydrogen phosphate (0.24 mg/mL), polysorbate 80  
(Tween 80) (0.001 mL/mL), and water for injection (to 1 mL), with a pH of 7.4 ± 0.5. The  
diluent is supplied in 50 mL vials with extractable volume 40 mL.  
 
A matching placebo is also provided as a sterile, clear, colorless to slightly yellow liquid for IM 
injection  in prefilled  vials  that are identical  in appearance  to the vials  containing  active  drug.  The 
placebo comprises of the same liquid used as a diluent for the active drug formulation.  
 
1.3 Preclinical  Data  
 
1.3.1 Entolimod’s  Mechanism  of Action  
The target of entolimod action, the TLR5 receptor, is found on the surface of both structural and 
immunological cell types, including multiple types of epithelia, intestinal crypt cells, intestinal 
endothelial cells on the basolateral surface of the intest inal epithelium, hepatocytes,  
mesenchymal stem cells, peripheral blood mononuclear cells, stromal elements of some 
hematopoietic organs, intestinal cluster of differentiation (CD) 11c+ dendritic cells and 
regulatory T -cells (T reg). 
 
Binding of entolimod to  TLR5 specifically activates NF -қB-dependent pathways [6,7]. This 
results in increased production of multiple factors, including cytokines (in particular, G -CSF and 
IL-6) [3], antioxidants and antiapoptotic factors, and promotes multiorgan tissue protectio n and 
regeneration through multiple mechanisms as shown in Figure 1 [5,6,8 –13]. Entolimod shows a 
similar half maximal effective concentration (EC50) for TLR5 -mediated activity as its parent, 
flagellin (FliC), when assessed by a reporter system comprised o f an NF -қB-dependent bacterial 
ß-galactosidase gene (LacZ) reporter [6]. 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  10 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Figure  1. Pharmacological  Response  to Entolimod  Binding  of TLR5  
 
 
Abbreviations:  AKT=protein  kinase  B, ARS=acute  radiation  syndrome,  CBLB502=entolimod,  G-CSF=granulocyte 
colony -stimulating factor, GI=gastrointestinal, HP=hemopoietic, IL=interleukin, NRF2=nuclear factor (erythroid 
derived 2) -like 2, P13K=phosphoinositide3 -kinase, ROS=reactive oxygen species, SOD2=superoxide dismutase 2, 
STAT3=signal transducer and activator of transcription 3, TLR5=Toll -like receptor 5  
 
1.3.2 Entolimod’s  Pharmacokinetics  
The pharmacokinetics of entolimod have been evaluated in mice and in non -human primates 
(NHP). Because entolimod is a small protein (35 kD), is composed of natural amino acids and 
does not contain any nonbiodegradable moieties, degradation of the  drug is expected  to occur  via 
ubiquitous proteases present in serum and via routes common to endogenous plasma proteins.  
For this reason, metabolism studies have not been performed. Nonclinical drug -drug interaction 
studies have not been performed.  
 
To evaluate the  PK of entolimod in mice, animals were injected IM with 1, 4, 12, 40, or 160 
μg/kg entolimod. Serum samples were collected at 0 (baseline, pre -injection), 0.5, 1, 2, 4, 8, and 
24 hours relative to entolimod injection. There were 36 mice in each dose group,  providing 6 
animals for serum collection at each time point. Due to assay sensitivity limitations, PK profiles 
for the 1 μg/kg and 4 μg/kg dose levels could not be determined. At doses of 12, 40 and 160 
μg/kg,  the time at which  the maximum  plasma  concentr ation  (Cmax) was observed  (Tmax) was 
~0.5 hours post -injection. Both C max and AUC increased in a dose -dependent fashion. After the 
Cmax was reached,  serum  concentrations  of entolimod  declined  rapidly  to undetectable  levels  by 
~4 hours  post-injection.  Elimination  showed  first-order  kinetics.  

Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  11 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 In healthy, research -naive, nonirradiated NHP given a single IM injection of 0.3, 1.0, 3.0, 6.6,  
10, 40, or 120 μg/kg entolimod, the drug was rapidly absorbed (median T max of ~1 hour) a nd 
rapidly eliminated (mean T 1/2 values ranging from 1.13 to 3.15 hours). Mean values for AUC 0-t, 
AUC 0-24, and AUC 0-∞ following doses of  0.3 to 120 μg/kg ranged from 0.139 to 273 ng•hour/mL,  
0.171 to 272 ng•hour/mL, and 0.199 to 273 ng•hour/mL, respectivel y, indicating that the  
majority of entolimod exposure occurs within 24 hours post -dose. Entolimod exposure showed 
no evidence of saturation over the dos range studied. An analysis of the dose -exposure 
relationship using dose -normalized C max and AUC over th e entire 400 -fold dose range studied 
indicates that both peak exposure (C max) and total exposures (AUC) were consistent with dose 
proportionality. Mean apparent clearance (Cl/F) values ranged from 536 to 1700 mL/hour/kg, 
which is ~20% to 65% of the liver b lood flow (2616 mL/hour/kg) for a 5 kg monkey. Mean 
apparent volume of distribution values (V d/F) ranged from 2090 to 3100 mL/kg, which is ~3 to 
4.5-fold greater than total body water (693 mL/kg) for a monkey weighing 5 kg. If systemic 
bioavailability from  the IM injection site was complete, these values would suggest moderate 
clearance and substantial distribution of entolimod into tissues. However, if distribution of this 
molecular -weight polypeptide molecule (MW ~35 kD) is limited to approximately the se rum 
space (nominal serum volume for monkey = 44.8 mL/kg [14]), the bioavailability of entolimod 
would be approximately 1.3% -3.5%, and the molecule would have a clearance of approximately 
75 mL/hour/kg after correcting for the bioavailable fraction.  
 
There were no apparent sex differences in entolimod pharmacokinetic parameters in either mice 
or NHP.  
 
1.3.3 Entolimod’s  Toxicology  
A study was conducted in CD -1 (ICR) BR mice to evaluate potential toxic effects of entolimod 
after a single subcutaneous (SC) injection at doses of 0, 0.02, 0.06, 0.2, 0.6, 2.0 or 6.0 mg/kg. 
Dosing  formulation  assays  revealed  that the actual  doses  delivered  were  0.067,  0.303,  1.22,  and 
4.71 mg/kg for the 4 highest entolimod dose groups. Each dose group included 10 males and 10 
females.  
 
Overall, there were no abnormal clinical signs observed, and no abnormalities in food 
consumption or body weight gain. Twenty -four hours after dosing, to tal white blood cell (WBC) 
counts were decreased in both males and females at entolimod doses ≥0.303 mg/kg. Animals 
given entolimod doses ≥0.067 mg/kg displayed decreases in serum alkaline phosphatase (ALP), 
alanine aminotransferase (ALT), and total biliru bin, and an increase in globulin 24 hours after 
dosing. Serum aspartate aminotransferase (AST) was increased 24 hours after dosing in females 
given  4.71 mg/kg  of entolimod.  Slight  decreases  in serum  triglycerides  were  noted  at all dosages. 
At 2 weeks after  dosing, serum sodium was decreased in mice given entolimod doses ≥0.067 
mg/kg; however, the means remained greater than or equal to the mean ±2 standard deviations 
reported for CD -1 mice. Serum calcium was also decreased 2 weeks after dosing at entolimod 
doses ≥1.22 mg/kg.  
 
There were no abnormal findings at necropsy, no effects on organ weights, and no 
histopathological changes indicative of entolimod toxicity. Overall, the only change attributed to 
entolimod  toxicity  in this study  was the increase  in AST  at the highest  dosage;  no other  clinical  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  12 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 pathological changes were considered indications of toxicity. Accordingly, the entolimod no - 
observed -adverse -effect level (NOAEL) in this study was reported as 1.22 mg/kg.  
 
Another study was conducted in rhesus monkeys to evaluate potential toxic effects of entolimod 
after a single  IM injection  at doses  of 0, 1, 3, 10, 30 and 100 μg/kg.  Formulation  assays  revealed  
the actual administered doses to be  0, 0, 0, 2.2, 13.2, and 62.5 μg/kg. Each dose  group  included 4 
males and 4 females.  
 
Administration of entol imod did not result in mortality or moribundity in any of the groups. 
Other than emesis on the day of dosing in 2 males in the highest dose group, no entolimod - 
related adverse clinical reactions were observed and there were no entolimod effects on body 
weight or temperature. Food consumption remained unchanged across all groups. 
Electrocardiograms (ECGs)  and ophthalmology  evaluations revealed  only incidental,  non-related 
findings.  
 
Overall, there were no significant test article -related alterations in any of the parameters of the 
performed clinical chemistry, hematology, coagulation and urinalysis evaluations. Increases in 
absolute neutrophil count (ANC) and decreases in absolute lymphocyte count (ALC) were 
observed 24 hours post -dose at entolimod doses ≥10  μg/kg (2.2 μg/kg actual). Some of the 
leucocyte changes were still evident 14 days post -dose. Decreases in serum phosphorus were  
also observed 24 hours post -dose at entolimod doses ≥10 μg/kg (2.2 μg/kg actual). Activated 
partial thromboplastin time (aPTT)  was increased 24 hours post -dose in males at 10 μg/kg (2.2 
μg/kg actual) and 30 μg/kg (13.2 μg/kg actual), but not at 100 μg/kg (62.5 μg/kg actual). There 
were no abnormalities in urinalysis.  
 
There were no abnormal findings at necropsy, no effects on org an weights, and no 
histopathological changes indicative of entolimod toxicity. The single occurrence of emesis on 
the day of dosing in some but not all high dose males was not considered to be an adverse event 
(AE).  The observed  changes  in leukocyte  counts  were  expected  from  the known  pharmacological 
action of the drug (cytokine induction) and were not considered adverse. The increases in aPPT 
were not considered to be entolimod -related due to the lack of a dose response. Therefore, the 
NOAEL in this study was reported as the highest do se administered 100 μg/kg (62.5 μg/kg 
actual).  
 
1.3.4 Immunosenescence  and Entolimod  
Aging  of mammals  is associated  with accumulation  of DNA  damage  in somatic  cells,  an increase 
in chronic systemic inflammation and reduced effectiveness of the immune system in clearing 
damaged cells. To a large extent, aging is the pathological manifestation of poisoning of the 
organism by these damaged cells and their products [15]. Ther efore, a study was performed to 
determine whether the immunomodulatory activity of entolimod could have anti -aging effects.  
Three experiments were performed in NIH Swiss mice. First, groups of male and female mice 
were treated with 5 daily injections of en tolimod (or PBS as a control) at 18 (“young”), 55 
(“middle -aged”) or 112 (“old”) weeks of age. Animal survival was monitored to determine 
effects of treatment on longevity (life span) and Physiological Frailty Index, a quantitative 
composite  of multiple  physiological  parameters,  was measured  at different  times  post-treatment  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  13 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 to determine effects of treatment on health status (health span/biological age). The results  
showed that entolimod did not significantly increase mouse life span but did h ave beneficial 
effects on health span (reduced PFI) in male NIH Swiss mice specifically when administered at 
“middle -age”. A second experiment then tested the immunomodulatory effects of entolimod 
delivered together with a vaccine (Prevnar13 pneumococcal v accine) to young, middle -aged or 
old male NIH Swiss mice. Entolimod was found to enhance the efficacy of vaccination (boosted 
antigen -specific antibody production), but only in the middle -aged group of mice. In addition, 
flow cytometric analysis of the T c ell repertoire in the spleens of middle -aged mice showed that, 
unlike in other age groups, co -administration of entolimod along with the vaccine resulted in a 
dramatic  reduction  in activated  T cells,  thus suggesting  that entolimod  enhances  their recruitment 
to peripheral sites of infection. The concordance of these results supports the hypothesis that the 
immunostimulatory  activity  of entolimod  can have  anti-aging  effects.  The third  experiment  in the 
study confirmed that entolimod improved vaccina tion efficacy in middle -aged male mice using 
an independent model (Tdap vaccine) and demonstrated that such effects were not dependent on 
the route of entolimod administration and were not improved by addition of alum adjuvant.  
 
Overall, this study demonst rated a stimulatory effect of entolimod on vaccination efficiency in a 
mouse model of age -related immunosenescence. This effect did not depend on the site of 
entolimod administration (indicating that it acts via a systemic mechanism) or on entolimod 
being part of the vaccine formulation. In addition, in “middle -aged” male mice, entolimod had a 
long-lasting positive effect on general health status that correlated with is immunomodulatory 
activity. Further studies are needed to clarify the mechanisms underlyi ng the age - and gender - 
dependence of these effects. It should be noted that these effects were observed with doses of 
entolimod that are lower than its optimal efficacious dose in acute radiation syndrome.  
 
1.4 Clinical  Data  to Date  
 
1.4.1 Overview  of Clinical  Prog ram 
To date, clinical studies with entolimod have been performed in healthy human subjects and 
patients with cancer. Data from two clinical studies performed in 150 healthy subjects comprise 
most of the entolimod safety database. Entolimod has also been ev aluated in 33 patients with 
advanced solid tumors and in 40 patients with colorectal cancer receiving entolimod as a 
neoadjuvant therapy before primary cancer surgery. Most recently, entolimod has been 
administered to 40 healthy subjects as an anti -addicti on vaccine adjuvant. The safety data  
derived from studies in cancer patients provide safety information for older patients and those 
with comorbidities.  
 
1.4.2 Clinical  Studies  in Healthy  Subjects  and Patients  with  Cancer  
 
1.4.2.1  Phase  1 Studies  in Healthy  Subjects  
Study HU -7014 was a first -in-human, sequential dose -escalation, single -dose study that  
evaluated  entolimod  doses  of 2 (N=6),  6 (N=6),  12 (N=6),  24 (N=6),  30 (N=12),  35 (N=6), 
40 (N=5), and 50 µg (N=3). Study  HU-9001 was a subsequent randomized stu dy of 4 groups of 
subjects that were administered one of the following dosing regimens: a single IM injection of  
25 µg of entolimod  (N=25),  two IM injections  of 30 µg  of entolimod  administered  72 hours  apart 
(N=24), a single IM injection of 35 µg of entoli mod (N=25), or a single IM injection of 35 μg of  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  14 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 entolimod preceded by 400 mg of orally administered ibuprofen (N=26). Dose selection for 
Study HU -9001 was intended to evaluate doses found to be readily tolerable in Study 7014, 
considering li mited experience with higher doses in a range of subject sizes. Given the 
similarities  of the subject  populations  and overlap  of the dose groups,  safety  data from 
Studies  HU-7014 and HU -9001 were integrated, focusing on the  effects of single -dose 
administration.  
In the combined healthy subject population of Studies HU -7014/HU -9001, subjects ranged in  
age from 18 to 55  years. Subjects were primarily Caucasian men of Hispanic ethnicity; however, 
women  and African  Americans  were also represented.  Body  weights  ranged  from  46.0 to 
109.5  kg but with few subjects at the extremes of the weight range. Demographic characteristics 
were reasonably well balanced across the dose groups. However, the 50 µg dose group was 
composed completely  of women. Mean body weights in the lower and middle dose groups were 
between ~74 kg and ~83 kg. In contrast, mean body weights were lower in the 40 µg and 50 µg 
dose groups (66 kg and 58 kg, respectively), resulting in high body -weight -adjusted doses 
(ranging to 1.09 g/kg) in these subjects.  
Pharmacokinetic data revealed a lag in the appearance of entolimod in the serum after IM 
injection, which resulted in a mean time of maximum concentration (T max) of 3 to 6 hours post - 
dose. Increases in maximum concen tration (C max) and AUC values with dose were somewhat 
greater than dose -proportional. Clearance from the circulatory system was rapid with the mean 
terminal elimination half -live (t ½) being ~3  hours. The pharmacokinetic profile of entolimod was 
not affecte d by pretreatment with the nonsteroidal anti -inflammatory drug (NSAID) ibuprofen.  
Administration of entolimod resulted in rapid and  substantial dose -related increases in plasma 
levels of G -CSF and IL -6. IL -8 and IL -10 were also elevated. Plasma cytokine levels typically 
peaked by 4  hours and decreased to pre -dose levels by 7 to 12 hours after injection. Increases in 
absolute neutrophi l count (ANC) were observed in all dose groups after entolimod 
administration, peaking by ~7 to 24  hours and returning to pre -dose levels by 5  days (120 hours) 
after injection. Administration of ibuprofen prior to entolimod dosing appeared to augment the 
entolimod -mediated increases in plasma concentrations of cytokines (e.g., G -CSF, IL -6, IL -8, 
IL-10) relative to administration of entolimod alone.  
Entolimod administration was associated with unpleasant, but transient and generally mild, 
adverse effects, wh ich were primarily comprised of elements of a flu -like syndrome (malaise, 
fatigue, chills, fever, myalgias, and nausea) that are consistent with TLR agonism. As  
specifically evaluated in the development program, the constitutional components of the flu -like 
syndrome could be lessened either preemptively or reactively with ibuprofen while still 
preserving the desired pharmacodynamic activity of entolimod.  
Transient increases in white blood cell count (WBC) and ANC and decreases in platelet count 
and absolute lymphocyte count (ALC) were seen in response to entolimod administration. These 
changes were considered to be components of the expected mechanism -related activity of 
entolimod, had no clinical sequelae, and were not considered adverse effects. Administration of 
entolimod was also associated with transient increases in serum levels of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), w ithout changes in serum levels 
of alkaline phosphatase (ALP) or bilirubin. Such hepatic transaminase changes are considered 
consistent with the mechanism of action of entolimod and may result from recruitment of large 
numbers  of natural  killer  cells to sites of TLR5  activation  such as the liver [16]. The data from  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  15 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Study  HU-9001 were modeled using the DiliSym ™ proprietary software that is currently the 
focus of a collaboration between the U.S. Food and Drug Administration (FDA) and The  
Hamner I nstitutes for Health Sciences  [17]. This analysis indicated that subjects given entolimod 
had a pattern of minor hepatocyte loss and recovery similar to that observed in healthy subjects 
receiving commercially available heparin drug products (e.g., heparin , dalteparin, enoxaparin, 
adomiparin). Other laboratory abnormalities associated with entolimod administration were 
asymptomatic hyperglycemia and transient hypophosphatemia. All of these laboratory 
abnormalities were perceived to be transient and self -limiting, have no serious clinical 
implications, and require no monitoring or intervention. Such effects were seen following 
administration  of IL -6 in patients with cancer [18] and, thus, are likely secondary consequences of 
entolimod -mediated induction of th is cytokine.  
Transient  decreases  in blood  pressure  and increases  in pulse  rate observed  in Studies 
HU-7014/HU -9001 were also likely the result of entolimod -mediated IL -6 induction  [19]. Most of 
the changes in blood pressure were within the normal range and were imperceptible to subjects, 
although a minority of study participants did describe diz ziness and orthostatic syncope occurred 
in 1 subject. For those subjects that developed blood pressures below the normal range, the time 
to return to normal averaged ~6 hours, indicating that hypotension following entolimod 
administration is typically not long lasting. No elevations of serum creatinine or blood urea 
nitrogen  (BUN)  consistent  with renal  hypoperfusion  were  evident  in any subject.  Observations  of 
hypotension  were  managed  at the investigator’s  discretion  in both Studies  HU-7014  and 
HU-9001. Con sequently, such changes were addressed inconsistently, with neither the minimum 
absolute blood pressure nor the maximum decrease from baseline necessarily prompting an 
investigator decision to administer intravenous (IV) fluids. Only 13 of 150 subjects (8. 7%) 
received IV fluids and only 1 subject (0.6%) was given IV dopamine; the rationale for 
administering a pressor agent to this subject was unclear since they only had transient 
asymptomatic Grade 2 hypotension and were discharged normotensive the followin g day.  
Electrocardiograms  (ECGs)  were  evaluated  in both clinical  trials  in healthy  subjects  at screening, 
pre-dose, at 2  hours and 4 hours post -dose on Day 1, and at follow -up on Day 4 or 5 following 
entolimod administration. No changes in PR or RR intervals were observed and no other 
abnormalities were apparent. Changes in corrected cardiac QT interval (QTc) ≥60 msec or 
evidence of prolonged QTc (>501 msec) occurred in only 4 subjects but showed no dose -, 
exposure -, or time -dependency that suggested an adverse entolimod effect. Based on the 
available data in healthy subjects, there is no indication that entolimod caused dist urbances of 
cardiac conduction or rhythm.  
Overall, the results of these clinical studies in healthy human subjects indicated variable but 
dose-dependent increases in pharmacokinetic and pharmacodynamic parameters, but no clear 
dose-related pattern of adver se effects on safety parameters. Nevertheless, it remains possible  
that dose -dependent changes in safety parameters (i.e., symptomatic events, laboratory 
abnormalities, and hemodynamic measures) could have been obscured by differences in body 
weight among study participants.  
 
1.4.2.2  Phase  1 Study  in Patients  with  Cancer  
Study I -196111 was a Phase I multi -center, dose -ranging study designed to determine the safety 
and tolerability  of entolimod  in patients  with advanced  cancers  [20,21]. Entolimod  doses  of 
5 (N=4),  10 (N=3),  15 (N=3),  20 (N=4),  30 (N=12),  and 40 (N=7)  µg were  evaluated  with IM 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  16 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 injections given once daily for 5 days (Days 1 -5) on a dose -per-subject basis through the 20 µg 
dose level and with IM injections once per day on Days 1, 4, 8, and 11 at the 30 µg and 40 µg 
dose levels.  
Subjects ranged in age from 27 to 82 years and were p rimarily male and Caucasian. Body 
weights ranged from 40.7 kg to 117.3 kg. Subjects had a variety of cancer types; colorectal 
cancer and lung cancer were most commonly represented.  
The safety results of Study I -196111 confirm that the commonly occurring AE s following from 
entolimod administration are reflective of a “flu -like” syndrome, including chills, pyrexia, 
nausea, and vomiting. Expected transient treatment -emergent increases in leukocytes and 
neutrophils and decreases in lymphocytes and platelets, as  well as treatment -emergent increases 
in serum ALT and AST levels, increases in serum glucose, and decreases in serum phosphate 
were observed. Expected transient, generally asymptomatic hypotension and tachycardia were 
also observed after entolimod injecti on; blood pressure recovered to pretreatment values with  
rest and fluids. When increases in QTcB occurred, they were almost universally low grade and 
did not show dose dependency; collectively, the ECG data do not suggest that entolimod causes 
clinically r elevant disturbances of cardiac rhythm or conduction. Overall, the safety profile of 
entolimod in subjects with advanced cancers was found to be consistent with that observed in 
healthy subjects.  
 
1.4.2.3  Phase  2 Study  in Patients  with  Cancer  
Study BL612 -CBLB502 was a Phase 2, multi -center, randomized, placebo -controlled, single - 
blind study designed to assess the safety, pharmacodynamic effects, and preliminary efficacy of 
neoadjuvant therapy with entolimod in subjects with colorectal cancer w ho had never received 
antitumor treatment and were scheduled for surgical resection of the primary tumor. Entolimod 
doses of 0.35 μg/kg or 0.45 μg/kg (not to exceed 30 μg or 40 μg per injection, respectively) or 
placebo was administered as either a single IM injection or as two IM injections separated by 3 
(±1) days, with the last injection administered 4 (± 2) days before surgical resection of the 
primary tumor. Absolute entolimod doses ranged from 18 to 40 μg. Subjects were given 
premedication  of 400 mg ibuprofen orally  30 (±  5) minutes  before  each injection  of study  drug to 
mitigate the flu -like syndrome found to be associated with administration of entolimod in earlier 
clinical studies.  
 
A total of 40 subjects were enrolled and randomized in a 3:1 ratio of entolimod (30 subjects) to 
placebo (10 subjects). Thirty -eight subjects received the planned number of injections of 
entolimod or placebo; 2 of the 30 entolimod -treated subjects who were assigned to receive 2 
injections of 0.45 μg/kg entolimod did not r eceive the second of the 2 planned doses due to the 
occurrence of SAEs (one subject 69 y/female 30 μg entolimod - bigeminal ventricular 
extrasystoles,  and the other  subject  78 y/male  33 μg entolimod - myocardial  infraction)  attributed 
to a history of ischemic heart disease. Subjects ranged in age from 33 to 84 years and were 45% 
male and 55% female and primarily Caucasian. Body weights ranged from 43.0 kg to 107.2 kg. 
Most subjects had Stage II or Stage III colorectal cancer.  
 
Both entolimod dose levels were well tolerated in this population. The commonly occurring AEs 
were reflective of the entolimod -associated “flu -like” syndrome, including chills, fever, 
headache,  and nausea.  Laboratory -related  AE reports  showed  the expecte d pharmacologic  effects 
of entolimod,  including  decreases  in lymphocytes,  increases  in liver transaminases,  an increase  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  17 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 in serum glucose, and a decrease in serum phosphate. Predicted findings of transient, generally 
asymptomatic hypotension a nd tachycardia were also observed after entolimod injection; blood 
pressure recovered to pretreatment values with rest and fluids. Predicted increases in plasma 
cytokines (G -CSF, IL -6, IL -8, IL -10) and increases in circulating neutrophils and decreases in 
circulating lymphocytes (including B cells, T -cell subsets, and NK cells) were observed in the 
entolimod -treated subjects. Overall, the safety and pharmacodynamic profiles of entolimod in 
subjects with colorectal cancer in this study were consistent with t hose observed in healthy 
subjects and in previous studies in subjects with advanced cancer.  
 
1.4.2.4  Entolimod  in Combination  with  Vaccine  
The Kadvax Technology study was performed to evaluate the safety and efficacy of 1 μg of 
entolimod receiving a commercial tet anus-diphtheria (Td) vaccine in healthy human subjects. 
The study enrolled 40 male volunteers (16 Caucasian, 24 non -Caucasian) between the ages of 18 
and 40 years old (mean age = 28 years). Fifteen volunteers were enrolled in the control group  
and given co mmercial Td vaccine alone while 25 volunteers received the Td vaccine in 
combination with 1 μg of entolimod. Tetanus - and diptheria -specific antibody titers were to 
determine if the addition of entolimod increased the vaccine response.  
 
Mean  baseline  level s of tetanus  toxoid  (TT) -specific  antibodies  were  relatively  high in this study 
(2.95 IU/mL), and as a result, no subjects in the control (Td alone) or test (Td+entolimod) group 
had TT antibody  responses  above 6 IU/mL.  Therefore,  only subjects  with pre-treatment -antibody 
titers below 3 IU/mL were included for data analysis (9 Td  alone and 11 Td+entolimod). Eighty - 
two percent of the subjects that received entolimod with the Td vaccine showed a 2 -fold or  
higher  increase  in their TT antibody  titers,  while  only 33% of the control  group  showed  this level 
of increase (chi sq = 4.3; p = <0.03). Two of the entolimod test subjects showed particularly 
strong increases in antibody titers (10 - and 15 -fold above baseline). A negative correlation was 
observed between baseline antibody titer and the change in antibody titer over 6 weeks. The 
correlation between lower baseline titer and greater post -vaccination change in titer was stronger 
in the Td+entolimod group than in the control group (r = -0.73 vs. -0.36). The negative 
correlation was statistically significant in the Td+entolimod test grou p with a p -value of <0.003. 
Analysis of anti -diphtheria antibody titers showed a greater increase in anti -diphtheria antibody 
titers  for all 25 Td+entolimod  test subjects  versus  the 15 Td alone  control  subjects  (averaging  1.1 
IU/mL vs. 0.9 IU/mL, respectiv ely; p = <0.02).  The negative correlation between baseline 
antibody titer and the change in anti -diphtheria antibody titer was also significantly stronger for 
the Td+entolimod group than for the control group (r = -0.91 vs -0.52, respectively).  
 
During this 6 -week clinical trial, there were no treatment -related adverse events reported. Thus, 
IM injection of 1 μg of entolimod together with Td vaccine was found to be safe and to 
significantly increase the Td vaccine response.  
 
1.4.2.5  Entolimod  Safety  in Elderly  Subjects  (≥65  years  old) 
Entolimod -specific treatment emergent adverse event (TEAE) data for 25 geriatric (≥65 years 
old) subjects was extracted from the studies performed in patients with advanced solid tumors 
(Study I -196111; 14 geriatric subject s) and in patients with colorectal cancer prior to primary 
tumor resection (Study BL612 -CBLB502; 11 geriatric subjects).  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  18 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 The geriatric subjects ranged in age from 65 to 84 years, with thirteen subjects between 65 and  
70 years, nine subjects b etween 71 and 80 years and three subjects between 81 and 84 years. 
There  were  8 females  and 17 males  with screening  body  weights  ranging  from  47.2 kg to 107 kg. 
Sixteen (64%)  of these  subjects had colorectal cancer, while  lung cancer  (n=4),  melanoma  (n=2),  
anal cancer (n=2) and urothelial cancer (n=1) were also represented. For analysis, subjects were 
stratified  into 3 groups  based  on the administered  entolimod  dose per kg of body  weight:  (i) 
<0.25  mg/kg,  (ii) 0.25 mg/kg  to 0.40 mg/kg,  and (iii) >0.40  mg/kg  with mean  body  weights  of 
77.7 kg, 79.1 kg, and 70.8 kg, respectively.  
 
All subjects experienced a TEAE, but there was little evidence of a dose response when 
considering the total frequencies of any given type of event. Altogether, 175 TEAEs were 
reported among the 25 (100%) geriatric subjects. There did not appear to be a dose trend within 
any of the system organ classes (SOC) including general disorders, administrative site  
conditions, and respiratory, thoracic and mediastinal disorders. A majority  (147) of the TEAEs 
were mild (Grade 1) or moderate (Grade 2) in intensity. Grade 3 TEAEs were largely laboratory 
abnormalities, except for single instances of cardiovascular events, including hypotension, 
hypertension and extrasystoles. The frequency of T EAEs of Grade ≥3 was nonexistent in the 
group receiving <0.25 mg/kg entolimod (<19.4 mg based on 77.7kg group mean body weight) 
but more prevalent in the group receiving >0.25mg/kg of entolimod (56%). Only 3/25 (12%) 
subjects ≥65 years experienced a Grade 4 AE (1 subject with hypophosphatemia, 1 subject with 
increased lipase, and 1 subject with both lymphocytopenia and neutrophilia). These subjects 
received a substantially higher entolimod dose (between 0.35 mg/kg and 0.45 mg/kg) than what 
is proposed for t he current study.  
 
No deaths occurred within this age group. Overall, within the limits of confidence imposed by  
the available number of geriatric subjects, there appear to be no differences in the safety profiles 
of people ≥65 years of age versus younger adult study subjects.  
 
1.4.2.6  Entolimod  and Subjects  with  TLR5  Mutation  
A mutation has been identified in the TLR5 gene in which a cytosine -to-thymidine transition at 
base pair 1174 changes an arginine at amino acid 392 to a stop codon (TLR5 392stop ) [22,23]. The 
TLR5 392 stop mutation is reported to occur in approximately 10% of humans in a heterozygous 
form and in 0.5% of the population in a homozygous form. The completed entolimod clinical 
trials described above included six subjects with TLR5 392 sto p mutations: 1 subject who was 
homozygous for the mutation and 5 subjects who were heterozygous for the mutation. The 1 
homozygous subject and 1 of the heterozygous subjects had almost no pharmacodynamic 
responses to entolimod. Of the remaining 4 heterozyg ous subjects, two had moderate responses 
and two had wild -type responses.  Due to the  small  number  of subjects with  TLR5 mutations, it is 
not possible to draw definitive conclusions, but the data suggest that it will not be useful to  
screen patients for the  presence of mutations in TLR5 prior to administration of entolimod. 
However, retrospective analysis of TLR5 functional status will prove useful for analysis in being 
able to definitively exclude non -responsive mutated TLR5 individuals.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  19 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 1.5 Dose  Rationale  
 
Based on pre -clinical and clinical studies described above (sections 1.3 and 1.4), we hypothesize 
that a single IM injection of entolimod may significantly increase levels of anti -influenza 
antibodies, promote increased immunity, and delay or alleviate aspects of frailty. Risk is reduced 
by using single doses 5 - to 50 -fold less than those which are likely to cause adverse events, such 
as hypotension. The route of administration provides local delivery to the site of vaccination 
where the ini tial immune response to influenza antigens will occur.  
 
1.6 Risks  and Benefits  
 
Entolimod used at doses similar to those to be used in this study has not previously been 
associated with adverse reactions. Based on the known safety profile of entolimod used at doses  
5 to 50 times those proposed in this study, the following potential risks may be associated with 
the investigational drug: (1) flu -like symptoms, (2) decreases in blood pressure, (3) increases in 
heart rate, (4) hepatic transaminase elevations, (5) h yperglycemia, and (6) hypophosphatemia.  
All potential risks, if realized, are expected to be transient. Since entolimod will be given only 
once, the likelihood of long -term consequences is expected to be very low. Potential benefits 
include: (1) increasing  influenza vaccine efficacy in an older population prone to poor vaccine 
responses, and (2) knowledge that might reasonably be expected from the study results (e.g., 
predicting early vaccine responses, better understanding of immunosenescence, and associat ions 
of vaccine responses with frailty). Therefore, the risks of using this drug are likely minimal 
compared to the anticipated benefits and the knowledge that may be gained from these clinical 
investigations.  
 
1.6.1 Definition  of DLT  
 
Reference should be made t o the Guidance for Industry Toxicity Grading Scale for Healthy  
Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials for grading the 
severity of AEs and laboratory abnormalities where applicable. Based on the known safety 
profile o f entolimod, flu -like symptoms are expected. Decreases in blood pressure, increases in 
heart rate, hepatic transaminase elevations, hyperglycemia, and hypophosphatemia are expected. 
DLT will be defined based on the sound clinical judgement of the investiga tor. DLTs will be 
considered adverse events and their time and grade severity will be recorded.  
 
These risks and benefits are outlined in the Informed Consent Form and listed in the  
Investigators Brochure.  
 
2 Study  Objectives  
 
Primary  Objective  
 
• To evaluate the effect of increasing dose of entolimod on enhancement of the influenza  
vaccine immunogenicity in the geriatric population (  65 years old).  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  20 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 • To characterize the safety profile of entolimod within the geriatric population (≥65 y ears 
old) vaccinated against influenza.  
 
Secondary  Objectives  
 
• To evaluate  the pharmacodynamic  effects  of entolimod  on immunological  status,  markers 
of senescence, viscoelasticity of tissue at the injection site, frailty indices and quality of 
life (QoL).  
 
Exploratory  Objectives  
• To determine  levels  of anti-COVID -19 serum -circulating  antibodies  in a population  of 
confirmed  COVID -19 cases  
 
• To determine the rate of the following occurrence in patients that become COVID -19 
positive: (i) disease progression requiring hospitalization; (ii) acute respiratory distress 
syndrome (ARDS); (iii) and 30 -day mortality following study drug administration.  
 
3 Study  Design  
 
This clinical trial is a randomized, double -blind, placebo -controlled, dose -escalated, single - 
administration study evaluating the immunogenicity, pharmacodynamics, and safety of  
entolimod within the geriatric population (≥65 years  old) vaccinated against influenza. After 
providing a written informed consent, subjects will undergo screening medical history, physical 
examination, vital signs, laboratory, and electrocardiogram (ECG) assessments within 28 days 
prior to study drug admin istration and influenza vaccination (see figure 2 below).  
 
Eligible subjects will be seen at the clinical trial research unit (CTRU) to receive the influenza 
vaccination (Fluzone, high -dose split virion influenza virus vaccine, Sanofi Pasteur) and a single  
IM injection of the study drug (entolimod or placebo). For safety assessment, initially 8 patients 
were to be enrolled in arm 1 (1ug) and accrual temporarily halted until the DSMB had assessed 
early adverse events. Due to the late seasonal start only four  patients were successfully accrued  
to the study by the  end of the flu season.  A safety report was generated and the DSMB endorsed 
proceeding with enrollment of arm 2 (3ug) and arm 1 will restart. After 8 subjects have been 
enrolled into arm 2, accrual for  arm 2 will be temporarily halted until the DSMB has assessed 
early adverse events.  A safety report will be generated and enrollment of arm 3 (10ug) will 
commence and arm 2 will restart. After 8 subjects have been enrolled into arm 3, accrual for arm 
3 wil l be temporarily halted until the DSMB has assessed early adverse events.  A safety report 
will be generated and enrollment of all three arms will continue until enrollment is complete.  
 
Unblinded and subject -level adverse event data will be provided to the  Data Safety Monitoring 
Board (DSMB).  If there is any evidence that higher doses are associated with adverse events, 
those  study  arms  may be dropped,  and the remaining  planned  patients  accrued  and randomized to 
remaining dose levels (and placebo) in equal proportions.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  21 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Subjects will be evaluated at the CRTU on the day of study drug administration (Day 1), for ≥ 6 
hours (2hrs, 4hrs and 6 hrs), thereafter day 2, weeks 1 and 4, and then on months 2, 6 and 12. 
Between month 2 and 6 and 6 and 12 AEs  will be reported and occurrence of respiratory 
infections will be assessed via phone interviews. Assessments of adverse events (AEs), vital 
signs/oxygen saturation including orthostatic measurements, clinical chemistry and hematology 
parameters (i.e., com plete blood count with differential), ECGs, plasma cytokines, leukocytes, 
anti- A/H1N1, anti -A/H3N2, and anti -B influenza serum circulating antibodies including cellular 
immune response outcomes will be performed to describe drug safety, pharmacodynamics, and 
immunogenicity.  
 
Subjects will be screened using a questionnaire for potential viral infection of COVID -19 at Day 
1 and monthly through the end of the study.  Subjects will be asked to provide a nasal swab and 
serum sample at Day 1 and Month 12. If at a ny time the subject is evaluated for COVID -19, the 
study team will document the symptoms, test results and treatment until resolution.  
 
 
Figure  2. Flowchart  of Study  Events  
NOTE:  Subjects  will also be contacted  every  two weeks  by phone  for Adverse  Event  monitoring.  
Day 7 Safety  Assessment  will be completed  as a remote  visit 

Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  22 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 3.1 General  Description  
 
3.2 Number  of Subjects  
 
A total of 100 individuals will be randomized into one of four treatment groups (placebo and 
three progressive dosage entol imod groups).  
 
3.3 Duration  of Participation  
 
After  consent, for each individual, the duration of participation will be for the length of time 
required to perform screening plus the 12 -month follow -up period after the single -dose 
administration of entolimod. It is anticipated that the screening will occur within seven days of 
written content.  
 
3.4 Primary  Study  Endpoints  
 
Immunogenicity  
 
• Changes of the anti - A/H1N1, anti -A/H3N2, and anti -B influenza virus strains serum 
circulating antibodies (as assessed using hemagglutination inhibition (HAI)  assay) levels.  
 
Safety  
• All adverse events (AEs), including dose limiting toxicities (DLTs); labor atory 
abnormalities; oxygen saturation and vital sign changes, and adverse electrocardiogram 
(ECG) findings  
 
3.5 Secondary  Study  Endpoints  
 
Pharmacodynamics  and Cellular  Immune  Responses  to Influenza  Vaccination  
 
• Time  to onset  and the number  of upper -respiratory  infections,  including  (but not limited 
to) influenza viral infections (as indicated by subject self -reporting)  
 
• Changes  in the concentration  of circulating  plasma  cytokines  including  (but not limited 
to): IL-6 and G-CSF as pharmacodynamic  indicators  of entolimod’s  activity  (measured 
using MSD assay platform)  
 
• Changes to 10 cytokine/chemokine mediators of adaptive immune function (IFN -γ, IL - 
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70,  IL-13 and TNF -α) in PBMC  culture  
supernatants  at 0 and 24 hours  after influenza  (A/H1N1,  A/H3N2  and B) viral stimulation 
as detected by Meso Scale Discovery, V -PLEX Proinflammatory panel human 
immunoassay kits.  
 
• Changes in the quantification of IFNγ -positive cells as a marker of cell -medi ated 
immunity (CMI) after vaccination using influenza virus -specific IFN -γ ELISPOT assay 
kits from R&D Systems.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  23 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
• Changes  in frailty  indices  and quality  of life (QoL)  of individuals  receiving  entolimod 
versus placebo  
 
• Changes  in measures  of physical  function  (6-minute  walk  test, grip strength)  and body 
composition  
 
3.6 Exploratory  Endpoints  
 
Sub-hertz  Analysis  of ViscoElasticity  (SAVE)  in muscle  tissue  in response  to local  immunological  
reactions due to influenza vaccination  
 
SAVE is a non -invasive imaging technique used to measure viscoelastic characteristics of tissue. 
This technique enables imaging biphasic characteristics of tissue which are related to both extra - 
cellular matrix changes as wells as disruption in the inters titial fluid mobility due to structural 
changes. A clinical study of this method in breast tumors has shown to provide effective 
separation of the benign from malignant breast lesions in patients [25]. 
 
In this study, SAVE  will be used for quantification  of muscle  reaction  in response  to vaccination, 
which  usually  occurs  within  few hours  of injection.  Vaccine  potency  and efficiency  are estimated 
by antigen -specific antibody titers and T -cell responses generated weeks after vaccination. 
Skeletal muscle cont ains few immune cells, but tissue resident and/or infiltrating immune cells 
encounter vaccine antigens for the first time at the site of administration. Thus, the magnitude of 
local innate immune responses starting at the vaccine delivery site (local infla mmation) initially 
controls subsequent adaptive immune responses and may be captured by SAVE.  
 
• Comparison  of SAVE  between  left versus  right  deltoid  muscles  of the same  individual.  
 
Markers  of Cell Senescence  
 
• Changes  in markers  of senescence  in blood  and urine.  
 
Efficacy  
• Reduction  of COVID -19 morbidity  (detection  of viral infection  by PCR)  
3.7 Primary  Safety  Endpoints  
 
Safety assessments are undertaken with the measurement of safety laboratory tests and 
procedures, vital signs, and recording of adverse eve nts. 
 
3.8 Identification  of Source  Data  
 
Source data will be obtained from the electronic medical record and documented in study  
specific case report forms (paper and/or electronic data capture). No information in source 
documents about the identity of the subjects will be disclosed.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  24 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 4 Subject  Selection  Enrollment  and Withdrawal  
4.1 Inclusion  Criteria  
 
Study  candidates  must  meet  all the following  criteria  within  1 week  prior  to entolimod 
administration to be eligible for participation in this study:  
 
1. Men and women of age  65 years and  older at  the time of enrollment  
2. Eligible  to receive  Fluzone  High -Dose  
3. Female  subjects  must  be past menopause  and not pregnant  
4. No history  of anaphylactic  reaction  to gelatin,  neomycin, or  other  vaccine  component  
5. Must  not have  had the flu vaccine within  the past 90 days 
6. Medically  stable  with no exacerbations  or changes  in medication  regimen  for chronic 
diseases in the past 3 months and no hospitalizations in the past 6 months  
7. Must be able to read/write English in order to provide informed consent and comply with 
study procedures  
8. Expected  to be available for  the duration  of the study  
 
4.2 Exclusion  Criteria  
 
Study  candidates  who meet  any of the following  criteria  within  28 days prior  to entolimod 
administration will not be eligible for participation in this study:  
 
1. Receipt  of any other  vaccines within  the past 30 days prior  to enrollment  
2. Acute  illness  within  the last 7 days without  systemic  signs  and symptoms  including  fever  
> 99.5 
3. History  of hypersensitivity  to the flu vaccine  or its components  (including  gelatin,  
formaldehyde, octoxinol, thimerosal, and chicken protein).  
4. History  of Guillain  Barré  syndrome  (GBS)  
5. History  of bleeding  disorders  
6. Medical  contraindication  to treatment  with vaccine  as indicated  by a history  of 
autoimmune disease, immune deficiency, or hype rsensitivity to other vaccines.  
7. Unstable  major  cardiovascular,  renal,  endocrine,  immunological  or hepatic  disorder  
8. Systolic blood pressure (SBP) < 110 mmHg or orthostatic hypotension [>20 mmHg fall  
in SBP or >10 mmHg fall in diastolic blood pressure (DBP) with standing] at the time of 
screening.  
9. Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper 
respiratory tract infections) (within 14 days prior to entolimod administration). Note: 
Subjects with localized fungal infection s of skin or nails are eligible.  
10. Baseline  vital signs  with  Grade  2 abnormalities  
11. Significant  cardiovascular  disease  (e.g.,  myocardial  infarction,  arterial  thromboembolism, 
cerebrovascular thromboembolism, venous thromboembolism) within 6 months prior to 
study drug administration; symptomatic  dysrhythmias or unstable dysrhythmias requiring  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  25 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 medical  therapy; angina  requiring  therapy;  symptomatic  peripheral  vascular  disease;  New 
York Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade ≥3 
hypertension (diastolic blood pressure ≥100 mmHg or systolic blood pressure ≥160 
mmHg) despite antihypertensive therapy.  
a. Significant screening ECG abnormalities, including unstable cardiac arrhythmia 
requiring medication, atrial fibrillation, 2nd -degree atrioventricular (AV) block type 
II, 3rd degree AV block, or Grade ≥2 bradycardia (within 14 days prior to entolimod 
admini stration).  
12. Inadequate  hepatic function  (within 14  days prior  to entolimod  administration):  
a. Serum  alanine  aminotransferase  (ALT)  3 × upper  limit  of normal  (ULN)  (Grade  
1). 
b. Serum  aspartate  aminotransferase  (AST)  3 × ULN  (Grade  1) 
c. Serum  alkaline  phosphatase  (ALP)  5 × ULN  (Grade  2) 
13. Serum  bilirubin  1.5 × ULN  (Grade   1) 
14. Positive  antiviral  serology:  
a. Positive hepatitis C virus (HCV) antibody or positive HCV ribonucleic acid (RNA)  
by quantitative PCR.  
b. Positive hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) 
antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by  
quantitative polymerase chain reaction (PCR) testing.  
15. Positive  human  immunodeficiency  virus  (HIV)  antibody.  
16. Use of medication that might interact with the flu vaccine including (but not limited to)  
specifically: aminopyrine, phenytoin sodium, theophylline, and warfarin sodium.  
17. Any ongoing  treatment  with immunosuppressive  or immune -stimulant  therapy  
18. Ongoing  use of systemic  corticosteroids.  
19. Blood or blood products given within the three months prior to vaccination and two 
months after vaccination  
20. Current  and/or  expected  receipt  of chemotherapy,  radiation  therapy  or any other  cytotoxic 
or immunosuppressive therapy [i.e. more than 10 mg of prednisone given daily or on 
alternative days for 2 weeks or more in the past 3 months]  
21. Receipt  of another  investigational  pharmaceutical  product  within  60 days of treatment  
22. Diagnosis of Parki nson’s Disease, previous stroke, or significant cognitive impairment 
(defined as MMSE <20)  
23. Other concerns that in the opinion of the PI would preclude a subject from participating  
in study procedures or from completing the study.  
 
4.3 Subject  Recruitment,  Enro llment  and Screening  
 
Recruitment sources include: 1) Mayo Clinic Patients 2) Mayo – RST Classified Advertising 3) 
Flyers  within  the community,  4) Newspaper  and Radio  Advertising,  5) Existing  lists/databases  of 
individuals interested in being contacted about participation in research studies, and 6) Social 
Media including Facebook. Subject recruitment and advertisement will occur on Mayo campus 
and at various sites off campus (e.g., retirement centers). Permis sion will be obtained from each 
location before recruitment begins.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  26 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
All patients  who meet eligibility  will be invited  to participate  in the study.  Potential  subjects  will 
be approached by trained clinical coordinators who will assist in recruitment and carry -through  
of the protocol. Written and informed consent will be obtained by appointed, trained study 
personnel. Please see Inclusion and Exclusion criteria above. Do cumentation of recruitment and 
enrollment efforts will be maintained in a secure institutionally -supported database. Only those 
subjects who provide informed consent will be enrolled in the study; we anticipate enrolling 100 
subjects.  
 
4.4 Early  Withdrawal  of Subjects  
 
4.4.1 When  and How  to Withdraw  Subjects  
 
The following conditions describe the circumstances under which a subject may be withdrawn 
from the study prior to that subject completing all of the study related procedures:  
• Any SAE  that precludes further  participation  of the subject;  
• With respect to subjects that have not received study drug, any SAE related to the study 
drug that in the opinion of the principle investigator or monitors as part of the Data and 
Safety Monitoring Plan (DSMP) which places subject s at high risk of experiencing the 
same SAE.  
• If in the opinion of  the principle investigator, there is doubt  that a subject, for any reason, 
can continue to fully participate in the study; and  
• Subject  decision  to withdraw  from  the study  (withdrawal  of consent). 
See also Section 10.1, “Study Monitoring Plan”.  
 
In the event  of a subject  withdrawal,  the following  will be performed:  
• Review  of data collected  through  the last in-person  or remote  visit for completeness;  
• Replacement of study subject if the subject did not receive study drug (i.e., early 
withdrawal before study drug administration); and  
• Follow -up for subje cts withdrawn from study, if the treatment visit was completed. The 
exit visit will include those study assessments and procedures that would have been 
performed at the next scheduled visit.  
 
4.4.2 Data  Collection  and Follow -up for Withdrawn  Subjects  
 
If a subject withdraws consent to participate in the study, for subject safety or other reasons, 
attempts will be made to obtain permission to collect follow up information whenever possible, 
including through medical chart review. As outlined in section 4.4.1 , “When and How to 
Withdraw Subjects,” the exit visit will include those study assessments and procedures that 
would have been performed at the next scheduled visit. Although early withdrawal could be 
related to the safety profile of the study drug, it cou ld also be related to other reasons, and thus 
follow -up assessments  could  be important  in capturing  both additional  safety  information as well 
as study outcomes that affect interpretation of risk versus benefit. Since the study drug will be 
given only once , long -term safety consequences related to participation are expected to be very 
limited.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  27 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 5 Study  Drug  
 
5.1 Description  
 
Study drugs (entolimod, diluent and placebo) are manufactured under current Good 
Manufacturing Practices (cGMP).  
 
The study sponsor will provide entolimod as a liquid for IM injection in 2 mL prefilled, single - 
use vials containing 50 µg of entolimod in 0. 5 mL (concentration of 100 µg/mL) of formulation. 
The formulation comprises phosphate -buffered saline (PBS) containing 0.1% polysorbate 80 
(Tween 80).  
 
For the dilution of 100 µg/mL entolimod the study sponsor will supply entolimod diluent in 50 
mL single use vials filled with 40 mL of phosphate -buffered saline (PBS) containing 0.1% 
polysorbate 80 (Tween 80).  
 
The study sponsor will also provide a matching placebo. The placebo has the same excipient 
composition as the active drug formulation (i.e., PBS cont aining 0.1% Tween 80) and fill - 
finished in the same type of 2 mL single use vials (0.5 mL per vial).  
 
Vials of entolimod and placebo should be kept frozen at -70 +/ - 10℃ and -20 =/ - 5℃ until 
thawed for use. Entolimod contained in vials and stored at -70 + /- 10℃ is stable for ≥7 years.  
The drug can withstand 3 freeze -thaw cycles. Entolimod should be thawed immediately before 
the dilution. Once thawed, study drug can be stored at 5 ⁰ +/- 3⁰C for up to 8 hours. Entolimod 
dilutions should be completed within th e established periods of stability for drug in the thawed 
vials. Diluted entolimod should be administered immediately after dilutions preparation.  
 
5.2 Treatment  Regimen  
 
A single IM injection of study drug (entolimod or placebo) will be administered to each subject 
on the morning of vaccination, Day 1 (to be administered within 1 inch and within 1 minute of  
flu vaccine). The appropriate amount of study drug will be aseptic ally withdrawn from the 
required number of study drug vials into a 1 -mL tuberculin syringe calibrated in 10 -µL units.  
The drug will be administered  from  the syringe  through  a 22-25-gauge  needle  (see table  1 below) 
at a 90o-angle to the skin surface into the deltoid muscle between the acromion process and the 
midaxillary line.  
 
Table  1. Needle  size. 
 
Female  or Male  up to 69 kg 22-25 gauge,  1 inch needle  
Female  70 kg to 91 kg, Male  70 kg to 118 kg 22-25 gauge,  1 inch to 1.5 in needle  
Female  > 91 kg, Male  > 118 kg 22-25 gauge,  1.5 inch needle  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  28 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 5.3 Method  for Assigning  Subjects  to Treatment  Groups  
 
Study subjects will be randomized in a dose -escalated 4 -arm study of entolimod in 3 possible 
doses  or placebo  (see table  2 below).  Beginning  in period  1, the first eight  patients  in the 1ug arm 
will be evaluated for safety and tolerability by the DSMB prio r to the enrollment of the  
remainder of the 1ug arm.  In addition, after review we will proceed with recruitment in period 2 
of the 3ug arm.  Again, safety and tolerability will be assessed in the first 8 patients of the 3ug 
arm during period 2. Similarly, a fter evaluation by the DSMB we will proceed with the  
remainder of the 3ug arm. In period 3 we will evaluate safety and tolerability in the first 8 
subjects of the 10ug arm. An evaluation by the DSMB will be completed and we will proceed 
with the remainder of the 10ug arm until all subjects have been accrued. We will recruit the 
balance of the subjects remaining to be enrolled (to obtain 25 subjects per arm) pending safety 
review by the DSMB.  
 
Randomization will be performed using Medidata Balance software, integrated into the  
electronic case report forms Medidata RAVE. A permuted block design will be used, with 
stratification by sex.  Subjects and study center personnel involved in the care of subjects will be 
blinded to study drug assignment (entolimod vs. p lacebo).  
 
Table  2. Dose -Escalated  4-arm Study  
Arm Placebo  1ug 3ug 10ug  
Period  1 2 6   
Period  2 2  6  
Period  3 2   6 
 
Dose  Levels  
Cohorts of subjects will be sequentially enrolled at progressively higher starting dose levels. The 
following dose levels are planned:  
• Dose  Level  1: 1 μg 
• Dose  Level  2: 3 μg 
• Dose  Level  3: 10 μg 
These doses are within the dose range of 1 μg to 10 μg and equa l or greater than five times less 
than that which has been previously evaluated in healthy subjects and patients with advanced 
solid tumors.  
 
5.4 Preparation  and Administration  of Study  Drug  
 
All dilutions of entolimod are performed in a biosafety cabinet under aseptic conditions by a 
licensed pharmacist on the  day of injection. The  drug dilution instructions for  each dose  level are 
described below and a summary of instructions is provided in T able 3.  
 
Dose  Level  1: 1 μg of entolimod  per injection  
Using 10 cc syringe remove 8.7 mL of diluent from 50 mL diluent vial and transfer this aliquot 
into 10 mL empty sterile vial. Using 0.3 or 1 cc syringe remove 0.3 mL of entolimod from the 
drug product  vial. Holding  the vial with 8.7 mL of diluent  upside  down  inject  0.3 mL of 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  29 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 entolimod  solution  directly  into the diluent  in the vial (dilution  1:30, final entolimod  
concentration  3.3 μg/mL).  Mix the vial by gentle rotation.  
 
Dose  Level  2: 3 μg of entolimod  per injection  
Using 3 cc syringe remove 2.7 mL of diluent from 50 mL diluent vial and transfer this aliquot 
into 10 mL empty sterile vial. Using 0.3 or 1 mL syringe remove 0.3 mL of entolimod from the 
drug product vial. Holding the vial w ith 2.7 mL of diluent upside down inject 0.3 mL of 
entolimod solution directly into the diluent in the vial (dilution 1:10, final entolimod 
concentration 10 μg/mL). Mix the vial by gentle rotation.  
 
Dose  Level  3: 10 μg of entolimod  per injection  
Using 1 cc  syringe remove 1 mL of diluent from 50 mL diluent vial and transfer this aliquot into 
the vial of drug product containing 0.5 mL of 100 μg/mL entolimod (dilution 1:3, final  
entolimod concentration 33.3 μg/mL). Mix the vial by gentle rotation.  
 
Table  3. Dilution  of 100ug/mL  Entolimod  for IM Injections.  
 
Dose 
level, 
μg Diluent 
volume, 
mL 100 μg/mL 
entolimod 
volume,  mL Diluted 
entolimod  
volume, 
mL  
Dilution 
factor  Diluted 
entolimod 
concentration,  
μg/mL  Injection 
volume, 
mL Number of 
injection  
syringes  that 
can be filled  
1 8.7 0.3 9 30 3.3 0.3 up to 26 
3 2.7 0.3 3 10 10 0.3 up to 6 
10 1 - 1.5 3 33.3 0.3 up to 4 
 
Placebo  group  
Remove  0.3 mL of  placebo  from placebo  vial using 1  cc syringe.  
 
Subjects will receive a single dose of study drug in the form of an IM injection. This injection is 
to be administered in the upper arm within 1 inch of the injection site of the influenza vaccine.  
 
5.5 Subject  Compliance  Monitoring  
 
Subject adherence to the s tudy treatment will be monitored by requiring the subjects to have the 
study  medication  administered  on-site in the Clinical  Research  and Trials  Unit (CRTU).  Records 
of study medication administration will be documented. Drug accountability will be noted.  
 
5.6 Prior  and Concomitant  Therapy  
 
Prior/concomitant  medications  will be assessed  at every  visit including  remote  visits.  
 
5.7 Packaging  
Entolimod, placebo and dilue nt will be shipped under cold conditions to the site in cardboard 
boxes containing 10 single -use vials per box placed into foam inserts. Entolimod vials should 
remain in the boxes in which they are supplied or stored in a manner that prevents glass -to-glass 
contact.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  30 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Solution  for Injection  0.1 mg/mL  Entolimod,  0.35 mL 
Date of Manufacture: 22 AUG 2011  
Lot Number:  
Manufactured  by: Wacker  Biotech  B.V.  (former  SynCo 
Bio Partners B.V. Amsterdam, Netherlands)  
Store  at: -70oС 
Mayo  Clinic  IRB # 19-004847; 
Dr. R. Pignolo  
Refer  to Clinical  Protocol  for Dosing  
Caution  – New  Drug  Limited  By Federal  Law  To 
Investigational Use  Solution  for Injection  0.1 mg/mL  Entolimod,  0.35 mL 
Date of Manufacture: 22 AUG 2011  
Lot Number:  
Manufactured  by: Wacker  Biotech  B.V.  (former  SynCo 
Bio Partners B.V. Amsterdam, Netherlands)  
Store  at: -70oС 
Mayo  Clinic  IRB # 19-004847; 
Dr. R. Pignolo  
Amount  in Box:  10 vials  
Refer  to Clinical  Protocol  for Dosing  
Caution  – New  Drug  Limited  By Federal  Law  To 
Investigational Use  
Solution  for Injection  Entolimod  Placebo,  0.35 mL 
Date of Manufacture: 18 AUG 2011  
Lot Number:  
Manufactured  by: Wacker  Biotech  B.V.  (former  SynCo 
Bio Partners B.V. Amsterdam, Netherlands)  
Store  at: -70oС 
Mayo  Clinic  IRB # 19-004847; 
Dr. R. Pignolo  
Refer  to Clinical  Protocol  for Dosing  
Caution  – New  Drug  Limited  By Federal  Law  To 
Investigational Use  Solution  for Injection  Entolimod  Placebo,  0.35 mL 
Date of Manufacture: 18 AUG 2011  
Lot Number:  
Manufactured  by: Wacker  Biotech  B.V.  (former  SynCo 
Bio Partners B.V. Amsterdam, Netherlands)  
Store  at: -70oС 
Mayo  Clinic  IRB # 19-004847; 
Dr. R. Pignolo  
Amount  in Box:  10 vials  
Refer  to Clinical  Protocol  for Dosing  
Caution  – New  Drug  Limited  By Federal  Law  To 
Investigational Use  
Entolimod  sterile  diluent,  40 mL per single  use vial 
Date of Manufacture: 25 MAR 2016  
Lot Number:  
Manufactured  by: AMRI  (Glasgow,  United  Kingdom) 
Store at: 2 -8oС 
Mayo  Clinic  IRB # 19-004847;  Dr. R. Pignolo  
Refer  to Clinical  Protocol  for Use 
Caution  – New  Drug  Limited  By Federal  Law  To 
Investigational Use  Entolimod  sterile  diluent,  40 mL per single  use vial 
Date of Manufacture: 25 MAR 2016  
Lot Number:  
Manufactured  by: AMRI  (Glasgow,  United  Kingdom) 
Store at: 2 -8oС 
Mayo  Clinic  IRB # 19-004847;  Dr. R. Pignolo 
Amount in Box: 10 vials  
Refer  to Clinical  Protocol  for Use 
Caution  – New  Drug  Limited  By Federal  Law  To 
Investigational Use  Both packaging boxes and individual vials will be labeled with the liquid contents, date of 
manufacture, lot number, manufacturer information, storage requirements, Mayo Clinic’s IRB 
number, the name of the PI and the federal investigational new drug use w arning. See Figure 3.  
 
Figure  3. Labels  for Experimental  Study  Drug  Vials  and Secondary  Shipment  Packages.  
 
Labels  for entolimod  vials  Labels  for secondary  entolimod  package  
 
 
Labels  for entolimod  placebo  vials  Labels  for secondary  entolimod  placebo  package  
 
 
Labels  for entolimod  diluent  vials  Labels  for entolimod  diluent  package  
 
 
 
5.8 Masking/Blinding  of Study  
In order to minimize the study bias, this study will use a process for randomized assignment to 
entolimod or placebo. The investigational drug blind will be maintained using the Research 
Pharmacy processes for preparation of the investigational product. Al l subjects and study 
personnel  except  for those  directly  involved  with study  drug preparation  will be blinded  to study  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  31 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 drug assignment for the entire study. All unblinded dosing information must be maintained in a 
secured area, accessible only by unblinded personnel.  
 
5.9 Receiving,  Storage,  Dispensing  and Return  
 
5.9.1 Receipt  of Drug  Supplies  
Per GPI request entolimod (study drug), entolimod placebo and entolimod diluent will be  
shipped overnight to Mayo Clinic from Almac (Souderton PA), clinical storage and distribution 
facility. Entolimod and entolimod placebo will be shipped on dry ice. Ento limod diluent will be 
shipped on cold packs. Temperature monitors will be enclosed in all packages . 
 
5.9.2 Storage  
All study medication will be provided by GPI.  Mayo Clinic Research Pharmacy will be 
responsible for the storage of medication. The storage conditio n for the study drug will be 
described on the medication label.  Medication must be stored in a safe, secure location with 
limited access.  
 
5.9.3 Dispensing  of Study  Drug  
The study drug is to be used exclusively in the clinical study according to the instructions  of this 
protocol  and directions  for use. The Investigator’s  designee is  responsible  for providing  subjects  with 
the study drug and instructions for dosing and proper storage of the study drug.  
 
The Investigator’s  designee  will record  the amount  of study  drug dispensed  and date of dispensing.  
 
5.9.4 Return  or Destruction  of Study  Drug  
At the completion of the study, there will be a final reconciliation of drug shipped, drug 
dispensed, drug returns, and drug remaining.  This reconciliation will be logged on the drug 
reconciliation form, signed and dated.  Any discrepancies noted will be do cumented and 
investigated, prior to return or destruction of unused study drug.  Drug destroyed on site will be 
documented in the study files.  
 
6 Study  Procedures  
 
The specific study procedures and time of activities to be conducted for each subject enrolled in 
the study are presented in tabular form in Table S -1. 
 
Physical examinations, other clinical evaluations, and additional laboratory studies or more 
frequent assessments may be performed consistent with appropriate medical care for the subject, 
but these  data will not necessarily be collected.  
 
In order to optimize scheduling convenience for the subject and for the study center staff, 
screening procedures may be performed over as many days as necessary within the specified 
screening period. For scheduled visits and follow -up periods the permitted visit windows are 
indicated in the table.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
following  tests will be performed:  
Page  32 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 For procedures to be performed at a specified time post -dose, the acceptable margin for actual 
time is the specified time ±10 minutes. If multiple procedures  are to be done at the same time 
point, the preferred order is vital signs, blood sampling, and then ECG, with blood sampling 
(particularly for pharmacodynamics) occurring as close as possible to the specified time.  
Missed procedures or evaluations should be performed as close to the originally scheduled 
date/time as possible. Based on the investigator’s judgment, an exception can be made when 
rescheduling  becomes  medically  unnecessary  because  it is too close  in time to the next scheduled 
procedure or evaluation. In that case, the missed evaluation may be omitted.  
 
6.1 Visit  1, Screening  Visit  (-28 to -7 days)  
 
A tabulated summary of all visits and assessments described in the following sections is provided in 
Table S -1, Schedule of Events. To the extent possible, subjects will be expected to adhere to the 
established visit schedule.  
 
After discussing the study w ith the investigator/appropriate study staff and after agreeing to study 
participation by signing the consent, subjects will be assigned a subject number. For any subject, it is 
the responsibility of the investigator or study team member to obtain written informed consent 
(subject’s signature) prior to performing any protocol -mandated assessment.  
 
However, assessments performed as part of the routine care of the subject may be used to assess 
eligibility. The subject number will identify the subject througho ut the study.  In case of re -screening, 
the subject number assigned during the first screening procedure will be retained.  
 
Patients  meeting  the entry  criteria  and consenting  to participate  in the protocol  will undergo  the 
following:  
• Eligibility  confirmation  and informed  consent  discussion  and documentation  
• Review  of medications  
• Brief  Physical  examination  
• Medical  history  
• Respiratory  infection  assessment  
• Demographic  Information  
• Quality  of Life (QoL)  questionnaire  
• Mini -Mental  State  Examination  (MMSE ) cognitive  status  assessment  
• ECG  – assessment  of QTc interval  
• Vital signs (orthostatic blood pressure, temperature, respiratory rate , height, weight, oxygen 
saturation and heart rate)  
• Blood work – screening labs [serum chemistry, hematology, coagulation, CMV, serum 
virology, cytokines, study drug related antibodies, long interspersed nuclear elements - 
(LINE -1), peripheral blood mononuclear cells (PBMCs) and biomarkers of senescence]  
• Urine collection  for urinalysis  
• Frailty Assessments (includes questionnaires, physical function testing and body  
composition)  
 
6.2 Visit  2, Treatment  Visit  – Day 0 
 
This visit will be recorded  as “Day  0” and will require  a visit to the research  center  where  the 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
following  tests will be performed:  
Page  33 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 • Vital signs (orthostatic blood pressure, oxygen saturation, temperature, respiratory rate , 
weight, and heart rate) prior to vaccine and investigational product administration and 2, 4 
and 6 hours post administration  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• COVID -19 Screening  questionnaire  
• Flu vaccine  administration  
• Investigational  product  administration  
• Nasal  swab  
• Blood work for pharmacodynamics, vaccine related antibodies, LINE -1, serum antibody 
testing,  and peripheral  blood  mononuclear  cells (PBMCs) prior  to vaccine  and investigational 
product administration and 2, 4 and 6 hours post administration  
• SAVE  procedures  (if applicable)  
 
After the observation period (6 hours) and prior to discharge from the Clinical Research and Trials 
Unit, a reassessment of vital signs including orthostatic blood pressures will be conducted on all  
study participants.  
 
6.3 Visit  3, Safety  Follow -up –Day 1 
 
This visit will be recorded  as “Day  1” and will require  a visit to the research  center  where  the 
following tests will be performed:  
• Brief  physical  examination  
• Vital  signs  (orthostatic  blood  pressure,  oxygen  saturation,  temperature,  respiratory  rate, 
weight, and heart rate)  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• Quality  of Life (QoL)  questionnaire  
• ECG  
• Blood  work  – labs [serum  chemistry,  Hematology,  coagulation,  cytokines,  LINE -1, and 
vaccine related antibodies ] 
• Urine  collection  for urinalysis  
 
6.4 Visit  4, Safety  Follow -up –Day 7 (remote  visit)  
 
This visit will be  recorded as “Day 7”  and will be a  remote  visit where  the following tests will  be 
performed:  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• Quality  of Life (QoL)  questionnaire  
 
6.5 Visit  5, Follow -up - Month  1 
 
This visit will be recorded  as “Month  1” and will require  a visit to the research  center  where  the 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  34 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 • Vital  signs  (orthostatic  blood  pressure,  oxygen  saturation  temperature,  respiratory  rate, 
weight, and heart rate)  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• Quality  of Life (QoL)  questionnaire  
• ECG  
• Blood work – labs [serum chemistry, Hematology, coagulation, CMV, cytokines, vaccine 
related antibodies, LINE -1, peripheral blood mononuclear cells (PBMCs) and biomarkers of 
senescence]  
• Urine  collection  for urinalysis  
 
6.6 Visit  6, Follow -up – Month  2 
 
This vi sit will be recorded as “Month 2” and will require a visit to the research center where the 
following tests will be performed:  
• Vital  signs  (orthostatic  blood  pressure,  oxygen  saturation  temperature,  respiratory  rate, 
weight, and heart rate)  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• Quality  of Life (QoL)  questionnaire  
• ECG  
• Blood  work  – labs [serum  chemistry,  Hematology,  coagulation,  cytokines,  vaccine  related 
antibodies, LINE -1, and peripheral blood mononuclear cells  (PBMCs)]  
• Urine  collection  for urinalysis  
• Frailty  Assessments  (includes  questionnaires,  physical  function  testing  and body 
composition)  
 
6.7 Visit  7, Follow -up – Month  6 
 
This visit will be recorded as “Month 6” and will require a visit to the research center where the 
following tests will be performed:  
• Vital  signs  (orthostatic  blood  pressure,  oxygen  saturation  temperature,  respiratory  rate, 
weight, and heart rate)  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• Quality  of Life (QoL)  questionnaire  
• ECG  
• Blood  work  – labs [serum  chemistry, Hematology, coagulation,  CMV,  cytokines,  LINE -1, 
and vaccine related antibodies]  
• Urine  collection  for urinalysis  
• Frailty  Assessments  (includes  questionnaires,  physical  function  testing  and body 
composition)  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  35 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 6.8 Visit  8, Follow -up – Month  12 
 
This visit will be recorded  as “Month  12” and will require a  visit to the research  center where  the 
following tests will be performed:  
• Vital  signs  (orthostatic  blood  pressure,  oxygen  saturation,  temperature,  respiratory  rate, 
weight, and heart rate)  
• Review  of medications  
• Review  of adverse  events  
• Respiratory  infection  assessment  
• Quality  of Life (QoL)  questionnaire  
• COVID -19 Screening  questionnaire  
• ECG  
• Nasal  Swab  
• Blood work – labs [serum chemistry, Hematology, coagulation, cytokines, and vaccine  
related  antibodies,  LINE -1, peripheral  blood  mononuclear  cells (PBMCs)  and serum  antibody 
testing]  
• Urine  collection  for urinalysis  
• Frailty Assessments (includes questionnaires, physical function testing and body  
composition)  
 
6.9 Monthly  phone  visits  – Month  3- Month  11 
 
The following  tests will be performed  remotely  (phone  visits):  
• Review  of adverse  events  
• Review  of medications  
• Respirato ry infection  assessment  
• COVID -19 Screening  questionnaire  
 
6.10 Examinations  and Procedures  
• Physical examinations  will be limited to cardiac, pulmonary, abdominal, integumentary, and 
gross neurological evaluation, and to other systems based on specific subject complaints.  
• Medical  history  is to be documented  at Screening  for each subject  
• Vital  signs , including  pulse,  orthostatic  blood  pressure,  heart  rate, respiratory  rate, oxygen 
saturation and temperature will be measured.  
• Height and weight  will be obtained at the screening visit; weight will be obtained at each 
additional visit. Body mass index (BMI) will be recorded.  
• A 12-lead electrocardiogram (ECG)  will be performed. The Investigator will review and 
assess all abnormal results for clinica l significance.  Any post -baseline ECG  
abnormalities assessed as clinically significant will be recorded as AEs.  
• Prior/Concomitant  medications  will be assessed  at every  site and remote  visit.  
 
6.11 Laboratory  Assessments  
The following laboratory assessments will  be collected at the time points specified in the 
schedule of events.  The Investigator will be provided all laboratory results and will review and 
assess out -of-range findings for clinical significance. Any post -baseline abnormal laboratory 
value assessed as clinically significant will be recorded as an AE.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  36 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Blood Tests:  
• Serum Chemistry  studies will include sodium, potassium, chloride, bicarbonate, BUN, 
creatinine, glucose, calcium, phosphorus, magnesium, total protein, albumin, ALT, AST, 
ALP, CK, LDH, GGT, total bilirubin, uric acid and CRP.  
• Hematology  parameters  will include  hematocrit,  hemoglobin,  erythrocyte count,  absolute 
counts of leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, 
platelet count.  
• Coagulation  studies  will include  PT and aPTT.  
• Virology evaluation  includes serum CMV, HIV antibody, HBsAg  antibody, HBc 
antibody, HCV antibody, Subjects will a positive antibody evaluation for HBc or HCV 
should  undergo  evaluation  for HBV  DNA  and for HCV  RNA  to determine  if the antibody 
test may be falsely positive.  
• PBMC Culture  Supernatant Assessment  will inc lude 10 cytokine/chemokine  mediators  of 
adaptive immune function (IFN -γ, IL -1β, IL -2, IL -4, IL -6, IL -8, IL -10, IL -12p70, IL -13 
and TNF -α) test performed using Meso Scale Discovery, V -PLEX Proinflammatory  
panel human immunoassay kits.  
• Serum for study related antibodies  includes influenza antibody titers against A/H1N1, 
A/H3N2, and B viruses, LINE -1, and entolimod specific neutralizing antibodies.  
• Plasma  for cytokines  will include  G-CSF and IL-6 tests will be performed  using  the MSD 
assay  platform as  well as senescence  biomarkers. These  samples will  be de -identified  and 
shipped to the sponsor, GPI, in a coded format.  Samples will be used for research 
purposes only as described in this protocol.  The data will be reported to the Mayo Clinic 
team for the analysis. When the study is completed, the sponsor will destroy any 
remaining samples.  
• COVID -19 testing will include COVID -19, PCR [SARS Coronavirus 2, Molecular 
Detection, PCR (NP)] and SARS -CoV -2 IgG Ab [SARS C oronavirus 2 IgG Ab, Serum]  
 
Urine  Tests:  
 
• Urinalysis will include specific gravity, pH, protein, glucose, ketones, bilirubin, 
urobilinogen, blood, nitrate, leukocyte esterase as assessed by dipstick and microscopic 
urinalysis evaluating white blood cells,  epithelial cell, bacteria, casts, and crystals.  
• Urine  will also be assessed  for senescence  biomarkers.  
 
6.12 MMSE  and Quality  of Life (QoL)  Assessments  
The Mini -Mental State Examination (MMSE) is a 30 -point questionnaire that is used to measure 
cognitive impairment.  It includes tests of orientation, attention, memory, language and visual - 
spatial skills.  
 
The Short Form (36) Health Survey will be administered to subjects. This survey cons ists of 36 
questions and eight scaled scores (vitality, physical functioning, bodily pain, general health 
perceptions, physical role functioning, emotional role functioning, social role functioning, and 
mental health).  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  37 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 6.13 Frailty  Assessments  
Frailty phenotyping will consist of 5 measures, including grip strength, walking speed, body 
composition, and questionnaires that will assess endurance and energy, unintended weight loss 
and physical activity level.  
 
Skin advanced glycation end products (AGEs ) will be assayed using an AGE Reader®. This non - 
invasive method has a light source that illuminates a skin surface of approximately 4 cm2 on the 
volar side of the forearm. The device uses an excitation light source with peak intensity of 
approximately 37 0 nm to excite fluorescent moieties in the tissue (skin autofluorescence), which 
then will emit light of a different wavelength. In the used wavelength band, the major 
contribution to fluorescence comes from fluorescent AGEs linked mostly to collagen. Emis sion 
light and reflected excitation light from the skin is measured with a spectrometer in the 300 –600 
nm range.  
 
6.14 SAVE  Assessments  
SAVE is a non -invasive imaging technique used to measure viscoelastic characteristics of tissue. 
This technique enables imagi ng biphasic characteristics of tissue which are related to both extra - 
cellular matrix changes as wells as disruption in the interstitial fluid mobility due to structural 
changes.  
 
6.15 Adverse  Events  
Adverse event monitoring will be conducted throughout the st udy for all subjects. The AE and 
serious adverse event (SAE) reporting period begins at the time of informed consent and 
continues through study completion. Adverse events will be assessed at every site and remote 
visit.  
 
The Investigator will follow -up on all AEs observed or reported by the subject up to the end of 
the reporting period or until follow -up is no longer necessary. The Investigator will follow -up on 
SAEs until they are considered resolved or the outcome is kno wn. 
 
Definitions, documentation, and reporting of AEs are described in  Section 8. Serious adverse 
events must be reported within 24 hours as described in Section 8.2.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  38 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Table  S-1. Schedule  of Events  
PERIOD  Screening 
Visit  Treatment 
Visit  Safety  Follow -Up Monthly 
Follow -Up 
ON-SITE  VISIT  1 2 3 4 (remote)  5 6 - 7 - 8 
WEEK  -4 0 Day 1 1       
MONTH   1 2 3 to 5[p] 6 7 to 11[p] 12 
Visit  Window,  week(s)  -28 days   1 day  1 week  
General  Eligibility,  Safety,  and Frailty Assessments  
Eligibility assessment  X          
Written  informed  consent  X          
MMSE  cognitive  status  assessment  X          
Frailty  assessments  [a] X     X  X  X 
Brief  physical  examination  [b] X  X        
Medical  history  X          
Demographic  Information  X          
Vital  signs/oxygen  saturation/Ht/Wt[c] X[q] X[d][q]  X[q]  X[q] X[q]  X[q]  X[q] 
12-lead ECG  X  X  X X  X  X 
AE assessment,  including  respiratory  infection 
assessment  X X X X X X X X X X 
Concomitant  medications  X X X X X X X X X X 
Quality  of life (QoL)  questionnaire  X  X X X X X X X X 
Study  Drug  Administration  
Study  drug  X         
Laboratory  Assessments  
Serum  chemistry[e] X  X  X X  X  X 
Hematology  [f] X  X  X X  X  X 
Coagulation  [g] X  X  X X  X  X 
Serum  virology [h] X          
Urinalysis  [i] X  X  X X  X  X 
Serum  for entolimod -reactive  antibodies[j] X  X  X X  X  X 
Plasma  for pharmacodynamics[k]  X         
Serum  for vaccine  related  antibodies [l]  X   X X  X  X 
Peripheral  blood mononuclear  cells (PBMC)[m]  X   X X    X 
COVID -19, PCR  [SARS  Coronavirus  2, Molecular 
Detection, PCR (NP)]   X        X 
 Exploratory  Procedures  
SAVE[n]  X         
Biomarkers  of senescence[o]  X   X   X  X 
SARS -CoV -2 IgG Ab [SARS  Coronavirus  2 IgG Ab, 
Serum]   X        X 
 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  39 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  Footnotes  
 [a] To be collected  at screening,  baseline,  months  2, 6 and 12 (includes  questionnaires,  physical  function  testing,  and body  composition)  
 [b] Physical  examination  will be limited  to cardiac,  pulmonary, abdominal,  integumentary,  and gross  neurological  evaluation,  and to other  systems  based  on specific  subject 
complaints.  
 [c] Height  will only be collected  at screening;  weight  will be collected  at all in-person  visits  
 [d] To be collected  pre-treatment  and 2, 4 and 6 hours  post treatment.  Wt will only be performed  prior  to study  drug administration.  
 [e] Serum  chemistry  studies  will include  sodium,  potassium,  chloride,  bicarbonate,  BUN,  creatinine,  glucose,  calcium,  phosphorus, magnesium,  total protein,  albumin,  ALT, 
AST, ALP, CK, LDH, GGT, total bilirubin, uric acid, and CRP.  
 [f] Hematology  parameters  will include  hematocrit,  hemoglobin,  erythrocyte  count;  absolute  counts  of leukocytes,  neutrophils,  lymphocytes,  monocytes,  eosinophils,  basophils; 
platelet count.  
 [g] Coagulation  studies  will include  PT and aPTT.  
 [h] Virology evaluation includes serum CMV, HIV antibody, HBsAg antibody, HBc antibody, HCV antibody. Subjects with a positiv e antibody evaluation for HBc or HCV 
should  undergo  evaluation  for HBV  DNA  and for HCV  RNA  to determine  if the antibody  test may be falsely  positive. Only  CMV  testing  will be carried  out on months  1 and 2. 
 [i] Urinalysis  will include  specific  gravity,  pH, protein,  glucose,  ketones,  bilirubin,  urobilinogen,  blood,  nitrite,  leukocyte  esterase  as assessed  by dipstick  and microscopic 
urinalysis evaluating white blood cells, red blood cells, epithelial cells, bacteria, casts, and crystals.  
 [j] Test will be performed  by GPI. Samples  may also be used for additional  testing  related  to the study  objectives.  
 [k] G-CSF and IL -6 tests will be performed  using  the MSD  assay platform.  Samples  are to be collected pre -treatment  and 2, 4 and  6 hours  post treatment.  
 [l] Influenza  antibody  titers  A/H1N1,  A/H3N2,  and B assessed  by HAI Assay  
 [m] Meso  Scale  Discovery,  V-PLEX  Proinflammatory  panel for  10 cytokine/chemokine  mediators  of adaptive  immune  function (IFN -γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL- 
12p70, IL -13 and TNF -α) and Interferon gamma ELISPOT assay  
 [n] Sub-hertz  Analysis  of ViscoElasticity (SAVE)  will be performed  6 hours  after study  drug administration (or  placebo)  on left and right  deltoid muscles  in cohorts  receiving 
entolimod (3μg and 10μg) and representing a total of 50 subjects.  
 [o] Blood  and urine  will be collected  for analyses  of senescence  
 [p] Subjects  will be contacted  bi-weekly  via the telephone  for remote  follow -up visits  
 [q] Orthostatic  blood  pressures  will be performed  at all visits  
Abbreviations:  AE=adverse  event,  ALP=alkaline  phosphatase,  ALT=alanine  aminotransferase,  aPTT=activated  partial  thromboplastin  time,  AST=aspartate  aminotransferase, 
BUN=blood urea nitrogen, CK=creatine kinase, CMV = cytomegalovirus, CRP=C -reactive protein, CTCAE=Common Terminology Criteria for Adverse Events, 
DNA=deoxynucleic acid, ECG=electrocardiogram, GGT=gamma -glutamyl transferase, HBc antibody=a nti-hepatitis B core antibody, HBsAg=hepatitis B surface antigen, 
HBV=hepatitis B virus, HCV=hepatitis C virus, HIV=human immunodeficiency virus, IV=intravenous, LDH=lactate dehydrogenase, PT =partial thromboplastin time, 
RNA=ribonucleic  acid, SARS -CoV -2 IgG Ab =  severe  acute respiratory syndrome  coronavirus 2  immunoglobulin G  antibody; SAVE= Sub -hertz Analysis  of ViscoElasticity,  
USP=United  State  Pharmacopeia,  PBMC=peripheral  blood  mononuclear  cells 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  40 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Supportive  Care  
 
General  Recommendat ions 
Consistent with subject safety and comfort, administration of any prescription or over -the- 
counter drug products other than study medication will be minimized during the study period, 
except those currently used for chronic medical conditions at the time of enrollment or those 
prescribed by the subject’s physician if not specifically contraindicated by the study design. 
Subjects will be discouraged from use of herbal remedies, self -prescribed drugs, tobacco 
products, alcohol, marijuana, or street drug s during their participation in the clinical study.  
 
If considered necessary for  the subject’s well -being, drugs  for concomitant medical conditions or 
for symptom management may be given at the discretion of the investigator. The investigator’s 
decision to  authorize the use of any drug other than study drug will take into account subject 
safety, the medical need, the potential for drug interactions, the possibility for masking  
symptoms of a more significant underlying event, and whether use of the drug will compromise 
the outcome or integrity of the study  
 
Subjects will be instructed about the importance of the need to inform the clinic staff of the use  
of any drugs or remedies (whether prescribed, over -the-counter, or illicit) before and during the 
course of the study.  
 
Recommendations with regard to specif ic types of concomitant therapies, supportive care, diet 
and other interventions are provided in the protocol. To minimize variations in supportive care, 
the recommended supportive care agents (e.g., loperamide, granisetron) should be used unless 
there is a medical rationale in a specific subject for use of an alternative product.  
 
Anti-inflammatory  or Antipyretic  Drugs  or Corticosteroids  
 
Anti-inflammatory or antipyretic drugs may not be administered prophylactically. Thereafter, 
subjects may receive ibupr ofen, 400 mg orally, as needed every 4 to 6 hours in response to 
constitutional symptoms, fever or malaise occurring following study drug administration. Other 
nonsteroidal anti -inflammatory drugs (NSAIDs) may be substituted as medically necessary.  
Post-entolimod use of acetaminophen, 650 mg orally as needed every 4 to 6 hours, may be used 
in response to constitutional or pyretic symptoms if medically necessary, but use of 
acetaminophen is not encouraged given its potential for adverse hepatic effects.  
 
The use of systemic, topical, inhaled, or enteric corticosteroids during screening or on Day 1 
should be avoided given that such drugs may confound interpretation of safety and 
pharmacodynamic responses in subjects on this study. However, such drugs are permi tted after 
study drug administration if a subject develops an intercurrent condition that require 
corticosteroid therapy.  
 
Support  for Hypotension  
In the event  that a subject  experiences  hypotension  (SBP  <90 mm Hg or DBP  <60 mm Hg; a > 
20 mm Hg drop in SBP or > 10 mm Hg drop in SBP with symptoms  at any time after 
administration  of study  drug or with orthostatics)  it may be managed  according  to standards  of 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  41 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 care until the SBP  is ≥90 mmHg and the DBP  is ≥60 mmHg on ≥2 determinations obtained ≥1 
hour apart [or until BP approaches within 10% of baseline (pre -study drug values) with  
resolution of symptoms]. It should be emphasized that a subject’s clinical condition, rather than 
blood pressure alone, should be the primary basis for any intervention or medical decision - 
making.  
• As much  as possible,  subjects  should  be kept at rest following  study  drug administration.  
• A subject requiring use of the bathroom should be evaluated for orthostatic changes. If  
the blood pressure is stable upon standing, and if the subject has no symptoms, the  
subject may ambulate to the bathroom, but study personnel should en sure the subject’s 
safety. If there is a clinically significant drop in systolic blood pressure, or the subject 
complains of lightheadedness upon standing, the subject should be encouraged to use an 
emesis basin, urinal, bedpan, or bedside commode, as appr opriate for the circumstances.  
• For any hypotension more significant than minor dizziness, treatment should follow 
standard clinic protocol.  
 
7 Statistical  Plan  
 
7.1 Sample  Size Determination  
 
A sample size of 25 per arm provides 90% power to detect a doubling (100% increase) in 
geometric  mean  influenza  antibody  titer A/H1N1 based  on a one -sided two -sample  t-test at alpha 
level 0.15.  This calculation assumes a coefficient of variation of 2.0 for  A/H1N1.  Under the 
assumption of smaller coefficient of variation for A/H3N2 and B antibody titers of 1.4, 25 per 
arm provides 90% power to detect an 80% increase in these antibody titers at alpha level 0.15. 
Thus, we plan to enroll 25 to each arm, for a t otal sample size of 100. We anticipate greater 
power under the ANCOVA approach, adjusted for baseline levels of the titer.  
 
7.2 Statistical  Methods  
The full analysis dataset will be based on a modified intent -to-treat principle.  Randomized 
subjects receiving b linded study drug will be included and analyzed based on their randomized 
assignment.  Patients meeting exclusion criteria or withdrawing after initial screening and 
randomization are excluded from all analyses.  Safety outcomes will analyze patients based on 
treatment received. Evaluable analysis sets will be defined and will include data from subjects 
who have the necessary baseline and on study measurements to provide interpretable results for 
specific parameter s of interest.  
 
Descriptive  Statistics  
Data will be described and summarized by study drug assignment (entolimod 1μg, 3 μg, 10 μg,  
or placebo) and time point.  Descriptive summaries will include sample size, mean and standard 
deviation, median, 25th and 75th percentiles, minimum and maximum for continuous variables 
and percentage for categorical variables.  Baseline/screening data will be summarized by 
randomized group using median (25th-75th) percentiles and percentage for continuous and 
categorical data, re spectively.  Study drug administration, concomitant medication use,  
supportive care use, AEs, laboratory abnormalities, vital signs/oxygen saturation, body weight, 
virology data, quality of life and frailty index status will be described and summarized.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  42 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Primary Hypothesis: We hypothesize that entolimod will cause an increase in influenza 
antibody titers at 4 weeks in comparison to placebo  
 
The distribution of antibody titers (A/H1N1, A/H3N2, B) during follow up is anticipated to be 
skewed based on reporting in prior studies and a log -transformation will be applied to these 
outcomes.  Antibody titers are measured at multiple time points in the first week after treatment, 
4 weeks, 2 months, 6 months, and 12 months.  A hierarchical mixed -effects regression model 
will be fit separa tely for the 3 endpoints, adjusting for the baseline/screening observation of the 
titer (an analysis of covariance (ANCOVA) approach).  The model will include random subject - 
specific intercepts and model time as discrete.  The primary outcome comparison is a contrast 
analysis of the outcome at 4 weeks comparing each entolimod dose to placebo.  As the overall 
aim of this study is to assess safety and identify potential efficacy of entolimod, especially the 
dose most likely to succeed in Phase III study, we app ly a one -sided test at alpha level 0.15 to 
each dose comparison (vs. placebo) and antibody titer combination, without multiplicity 
adjustment.  The primary analysis will be conducted using the modified intent -to-treat analysis 
dataset.  
 
Secondary Hypotheses : Secondary and exploratory endpoints require a variety of standard 
statistical methods.  
 
Key secondary endpoints include the frailty indices, measures of physical function (6 minute 
walk test and grip strength), and quality of life (QOL).  Frailty indices are measured at 2, 6, and 
12 months and QOL measured at each study visit.  For these outcomes, linear mixed effects 
models will assess the relationship between randomized arm and outcomes over time.  Discrete 
times will be considered corresponding to the stu dy visit and secondary analyses may consider 
continuous linear time (constant slope over time) for changes in the outcome.  For these 
outcomes, the 12 month observation is the primary comparison.  
 
Upper respiratory infections, including influenza, will be r ecorded over the follow up period.  
We anticipate the total number of these will be infrequent.  Thus, we compare the outcome of 
any infection (vs. no infection) across randomized arms using a Pearson chi -square test or 
Fisher’s exact test.  Secondary approac hes may consider analysis of the ordinal count of the 
number of infections, analyzed using a trend test.  
 
Cellular immune response and pharmacodynamics parameters, including concentration of 
circulating plasma cytokines and cytokine response to virial stim ulation are outcomes compared 
using analysis of variance (ANOVA) methods across the four comparison groups. 
Pharmacodynamic measures will be listed and will be summarized using appropriate graphical 
and tabular methods. Statistical analysis evaluating phar macodynamic parameters will be 
performed using contrasts in the context of analysis of covariance (ANCOVA).  
 
Handling  of Missing  Data  
In the analysis of primary outcomes, data are analyzed using a hierarchical regression approach 
assuming missing  data are  missing at random.  In a secondary approach, patients with dropout or 
missing follow up due to influenza viral infection during follow up will be assumed missing not 
at random  and missing  data will be imputed  to the baseline/screening  value  reflecting  no increase  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  43 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 from baseline in antibody titers among these patients.  Dropout for other causes will be 
considered similarly, except death unrelated to influenza, which will continue to be assumed as 
missing at random.  
 
Interim  Analysis  
No interim  analysis  will be performed  for efficacy  assessment.  
 
Multiplicity  
No adjustment s will be made for multiplicity correction to dose comparisons or the primary 
endpoints as the study aim is to identify promising doses for subsequent phase III study. 
Secondary outcomes will also not be adjusted for multiple comparisons.  
 
7.3 Subject  Populati on(s)  for Analysis  
The primary analysis uses a modified intent -to-treat principle.  Patients will be analyzed based  
on randomized arm using methods described previously.  Exploratory analyses will assess 
whether a differential sex -based response to treatment  exists for the primary outcomes and 
secondary outcomes of FI and QOL, using interaction terms in regression models.  
 
8 Safety  and Adverse  Events  
For safety  analyses, AEs will be classified using the Medical Dictionary for Regulatory  
Activities (MedDRA). The severity of AEs will be graded by the investigator according to the 
Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunte ers 
Enrolled in Preventive Vaccine Clinical Trials. Concomitant medication use will be coded using 
the World Health Organization Drug Dictionary (WHODRUG) into Anatomical Therapeutic - 
Chemical classification (ATC) codes; these data descriptions will partic ularly focus on  
supportive  medications and  care provided  in response  to any study -study -induced adverse  effects 
and to therapies for GVHD. For ECG assessment of QT intervals, correction by both the Bazett 
and Fridericia methods will be applied, and the dat a will be summarized by CTCAE grading 
categories in terms of absolute QTc and maximal QTc change from baseline.  
 
A safety  analysis will be conducted after 20 patients (5 per arm) have been randomized and 
completed the one -week safety follow -up period.  After the last subject has completed their one - 
week safety follow -up period, there will be a temporary halt in additional pa rticipation pending 
analysis of safety outcomes, anticipated to be no longer than seven days. A safety report will be 
generated after the 20th patient completes 1 week follow up, summarizing all adverse events 
overall and by study arm while maintaining bli nd (groups denoted as A -D in random order).  If 
appropriate, as  described below,  unblinded  and subject -level  adverse  event  data will be provided. 
Adverse events, both short term (14 days) and long term (through 365 days), will continue to be 
collected with ongoing monitoring as specified in the Data Safety Monitoring Plan (DSMP).  
 
8.1 Definitions  
Unanticipated  Problems  Involving  Risk  to Subjects  or Others  (UPIRTSO)  
Any unanticipated  problem  or adverse  event  that meets the  following  three  criteria:  
• Serious : Serious problems or events that results in significant harm, (which may be 
physical, psychological, financial, social, economic, or legal) or increased risk for the 
subject or others (including individuals who are not research subjects). These include: ( 1) 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  44 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 death; (2) life threatening adverse experience; (3) hospitalization - inpatient, new, or 
prolonged;  (4) disability/incapacity - persistent  or significant;  (5) birth  defect/anomaly;  (6) 
breach of confidentiality and (7) other problems, even ts, or new information (i.e. 
publications,  DSMB reports,  interim  findings,  product  labeling  change) that  in the opinion 
of the local investigator may adversely affect the rights, safety, or welfare of the subjects 
or others, or substantially compromise the  research data, AND  
• Unanticipated : (i.e. unexpected) problems or events are those that are not already 
described as potential risks in the protocol, consent document, not listed in the 
Investigator’s Brochure, or not part of an underlying disease. A proble m or event is 
"unanticipated" when it was unforeseeable at the time of its occurrence. A problem or 
event is "unanticipated" when it occurs at an increased frequency or at an increased 
severity than expected, AND  
• Related : A problem  or event  is "related"  if it is possibly  related  to the research  procedures.  
 
Adverse  Event  
An untoward or undesirable experience associated with the use of a medical product (i.e. drug,  
device, biologic) in a patient or research subject.  
Serious  Adverse  Event  
Adverse  events  are classified  as serious  or non-serious.  Serious  problems/events  can be well 
defined and include;  
• death  
• life threatening  adverse  experience  
• hospitalization  
• inpatient,  new,  or prolonged;  disability/incapacity  
• persistent  or significant  disability  or incapacity  
• birth defect/anomaly  
 
and/or per protocol may be problems/events that in the opinion of the sponsor -investigator 
may have adversely affected the rights, safety, or welfare of the subjects or others, or 
substantially compromised the research data.  
 
All adverse  events  that do not meet  any of the criteria  for serious,  should  be regarded  as non- 
serious adverse events . 
 
Adverse  Event  Reporting  Period  
For this study, the study treatment follow -up period is  defined as (365) days following the last  
administration of study treatment.  
 
Preexisting  Condition  
A preexisting condition is one that is present at the start of the study.  A preexisting condition 
should be recorded as an adverse event if the frequency, in tensity, or the character of the 
condition worsens during the study period.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  45 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 General  Physical  Examination  Findings  
At screening, any clinically significant abnormality should be recorded as a preexisting  
condition.  At the end of the study, any  new clinically significant findings/abnormalities that 
meet the definition of an adverse event must also be recorded and documented as an adverse 
event.  
 
Post-study  Adverse  Event  
All unresolved  adverse events  should  be followed  by the sponsor -investigator  until the events  are 
resolved, the subject is lost to follow -up, or the adverse event is otherwise explained.  At the last 
scheduled visit, the sponsor -investigator should instruct each subject to report, to the sponsor - 
investigator, any subsequent event( s) that the subject, or the subject’s personal physician, 
believes might reasonably be related to participation in this study.  
 
Abnormal  Laboratory  Values  
A clinical laboratory abnormality should be documented as an adverse event if it changes from 
value within the normal range before treatment to one outside and worse than the normal range 
after treatment. Such changes will prompt a repeat test, telephone c all to check the subject’s 
status, a repeat visit, and/or referral to the subject’s primary care physician.  
 
Hospitalization,  Prolonged  Hospitalization  or Surgery  
Any adverse event that results in hospitalization or prolonged hospitalization should be 
documented and reported as a serious adverse event unless specifically instructed otherwise in 
this protocol.  Any condition responsible for surgery should be documente d as an adverse event 
if the condition meets the criteria for an adverse event.  
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an 
adverse event in the following circumstances:  
 
• Hospitalization or prolonged h ospitalization for diagnostic or elective surgical procedures 
for a preexisting condition. Surgery will not be reported as an outcome of an adverse  
event if the purpose of the surgery was elective or diagnostic and the outcome was 
uneventful.  
• Hospitalizati on or prolonged hospitalization for therapy of the target disease of the study, 
unless it is a worsening or increase in frequency of hospital admissions as judged by the 
clinical investigator.  
• A visit to the emergency department or other hospital departmen t <24 hours, that does not 
result in admission (unless considered an important medical or life -threatening event).  
• Elective  surgery  planned  prior  to signing  consent.  
• Admissions  as per protocol  for a planned  medical/surgical  procedure.  
• Routine health assess ment requiring admission for baseline/trending of health status (e.g., 
routine mammogram).  
• Medical or surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation will be obtained in these cases.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  46 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Recording  of Adverse  Events  
At each contact with the subject, the study team m ust seek information on adverse events by 
specific questioning and, as appropriate, by examination.  Information on all adverse events 
should be recorded immediately in the source document, and also in the appropriate adverse 
event section of  the case repor t form (CRF)  or in a separate  adverse event worksheet.  All clearly 
related signs, symptoms, and abnormal diagnostic, laboratory or procedure results should 
recorded in the source document.  
 
All adverse events occurring during the study period must be recor ded. The clinical course of 
each event should be followed until resolution, stabilization, or until it has been ultimately 
determined that the study treatment or participation is not the probable cause.  Serious adverse 
events that are still ongoing at the end of the study period must be followed up, to determine the 
final outcome.  Any serious adverse event that occurs during the Adverse Event Reporting  
Period and is considered to be at least possibly related to the study treatment or study 
participation sho uld be recorded and reported immediately.  
 
8.2 Reporting  of Serious  Adverse  Events  and Unanticipated  Problems  
When an adverse  event  has been  identified, the study  team will  take appropriate action  necessary 
to protect the study participant and then complete th e Study Adverse Event Worksheet and log. 
The sponsor -investigator will evaluate the event and determine the necessary follow -up and 
reporting required.  
 
8.2.1 Sponsor -Investigator  reporting:  notifying  the Mayo  IRB 
Information  collected  on the adverse  event  worksheet  (and entered  in the research  database) : 
• Subject’s  name:  
• Medical  record  number:  
• Disease/histology  (if applicable):  
• The date the adverse  event  occurred:  
• Description  of the adverse  event:  
• Relationship  of the adverse  event  to the research  (drug,  procedure,  or intervention*):  
• If the adverse  event  was expected:  
• The severity  of the adverse  event:  (use a  table  to define  severity  scale  1-5**) 
• If any intervention  was necessary:  
• Resolution:  (was  the incident  resolved  spontaneously  or after discontinuing treatment)  
• Date  of Resolution:  
 
The Investigator will review all adverse event reports to determine if specific reports need to be 
made  to the IRB  and FDA.  The sponsor -investigator  will report  to the Mayo  IRB any UPIRTSOs 
and Non -UPIRTSOs acc ording to the Mayo IRB Policy and Procedures. The sponsor - 
investigator will sign and date the adverse event report when it is reviewed. For this protocol, 
only directly related SAEs/UPIRTSOs will be reported to the IRB.  
 
Relationship  
The relationship of a n AE to the Investigational Drug is a clinical decision by the sponsor - 
investigator (PI) based on all available information at the time of the completion of the CRF and 
is graded as follows:  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  47 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
  
1. Not related: a reaction for which sufficient information exists to indicate that the etiology is 
unrelated to the study drug; the subject did not receive the study medication or the temporal 
sequence of the AE onset relative to administration of the study medication is not reasonable or 
the event is c1early related to other factors such as the subject's clinical state, therapeutic 
intervention or concomitant therapy.  
 
2. Unlikely: a clinical event, including laboratory test abnormality, with a temporal relatio nship 
to drug administration which makes a causal relationship improbable and in which other drugs, 
chemicals, or underlying disease provide plausible explanations.  
 
3. Possible: a clinical event, including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug but which could also be explained by concurrent disease 
or other drugs or chemicals; information on drug withdrawals may be lacking are unclear.  
 
4. Probable: a clinical event including laboratory test abnormality, with a reasonable time 
sequence to administration of the drug, unlikely to be attributed to concurrent disease or other 
drugs or chemicals and which follows a clinically reasonable response on withdrawal (de - 
challenge): re -challenge information is not required  to fulfi1 this definition.  
 
5. Definite: a reaction that follows a reasonable temporal sequence from administration of the 
drug, or in which the drug level has been established in body fluids or tissues, that follows a 
known  or expected  response  pattern  to the suspected  drug,  and that is confirmed  by improvement 
on stopping or reducing the dosage of the drug, and reappearance of the reaction on repeated 
exposure (re -challenge).  
 
Severity  
The maximum intensity of an AE during a day should be graded according to the definitions 
below and recorded in deta ils as indicated on the CRF. If the intensity of an AE changes over a 
number of days, then separate entries should be made having distinct onset dates.  
 
1. Mild: AEs are usually transient, requiring no special treatment, and do not interfere with 
patient’s daily activities.  
 
2. Moderate: AEs typically introduce a low level of inconvenience or concern to the patient and 
may interfere with daily activities, but ar e usually ameliorated by simple therapeutic measures.  
 
3. Severe: AEs interrupt a patient's usual daily activity and traditionally require systemic drug 
therapy or other treatment.  
 
8.2.2 Sponsor -Investigator  reporting:  Notifying  the FDA  
The sponsor -investigator wi ll report to the FDA all unexpected, serious suspected adverse 
reactions according to the required IND Safety Reporting timelines, formats and requirements.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  48 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 Unexpected fatal or life threatening suspected adverse reactions where there is evide nce to 
suggest a causal relationship between the study drug/placebo and the adverse event, will be 
reported as a serious suspected adverse reaction.  This will be reported to the FDA on FDA 
Medwatch Form 3500A, no later than 7 calendar days after the sponso r-investigator’s initial 
receipt of the information about the event.  
 
Other  unexpected  serious suspected adverse  reactions where there is evidence  to suggest a  causal 
relationship between the study drug/placebo and the adverse event, will be reported as a serious 
suspected adverse reaction.  This will be reported to the FDA on FDA Medwatch Form 3500A, 
no later than 15 calendar days after the sponsor -investigator’s initial receipt of the information 
about the event.  
 
Any clinically important increase in the rate of serious suspected adverse reactions over those 
listed in the protocol or product insert will be reported as a serious suspected adverse reaction. 
This will be reported to the FDA on FDA Medwatch Form 3500A n o later than 15 calendar days 
after the sponsor -investigator’s initial receipt of the information about the event.  
 
The sponsor -investigator must also notify the FDA (and sponsors  must notify all participating 
investigators) in an IND safety report of pote ntial serious risks, from clinical trials or any other 
source, as soon as possible, but in no case later than 15 calendar days after the sponsor 
determines that the information qualifies for reporting under § 312.32(c)(1)(i) -(iv). 
 
Findings from other stud ies in human or animals that suggest a significant risk in humans 
exposed to the drug will  be reported.  This will be reported to the FDA on FDA Form 3500A, no 
later than 15 calendar days after the sponsor -investigators initial receipt of the information ab out 
the event.  
 
8.3 Unmasking/Unblinding  Procedures  
The investigational drug blind shall not be broken by the investigator unless information 
concerning the investigational drug is necessary for the medical treatment of the subject. In the 
event of a medical e mergency, if possible, the sponsor -investigator or PI should be contacted 
before the investigational drug blind is broken to discuss the need for unblinding.  
 
If the PI decides emergency unblinding is medically necessary, the PI needs to contact the 
Resear ch Pharmacy. The sponsor -investigator must be notified as soon as possible if the 
investigational drug blind is broken. The date, time, and reason the blind is broken must be 
recorded in the source documents, CRFs or Event forms/logs.  
 
8.4 Stopping  Rules  
A pre-specified  safety  assessment  will be conducted  after 20 subjects  (5 per arm)  have  completed 
a one -week safety follow up period.  Initial reports will maintain blinding of study arms.  If any 
study arm reports a serious adverse event or ≥ 2 total adverse e vents that are possible, probable, 
or definite relation to the investigational study drug, study arms will be unblinded and data 
provided to an independent monitor as specified in the DSMB.  Active high dose arms may be 
stopped early if safety concerns aris e related to the investigational drug.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  49 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 8.5 Medical  Monitoring  
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her 
site. This safety monitoring will include careful assessment and appropriate reporting of adverse 
events as noted above, as well as the construction and im plementation of a site data and safety - 
monitoring plan (see section 10 “Study Monitoring, Auditing, and Inspecting”).  Medical 
monitoring will include a regular assessment of the number and type of serious adverse events.  
 
8.5.1 Internal  Data  and Safety  Monitori ng Board  
A four person DSMB (clinical researchers) not affiliated with the study will be responsible for 
evaluating the progress of the study and will be provide unblinded data on a regular basis to 
monitor patient safety. This committee will communicate b y meeting every other week during  
the enrollment phase as the study team will be utilizing a dose -escalated recruitment strategy. 
The DSMB members will be responsible for determining if and when the next dose can be 
administered in a subset of subjects or if the study must be discontinued as a result of excessive 
adverse events.  Study data will be provided to the DSMB by the data coordinating center 
(including all adverse event reports). Data will be reviewed by the DSMB in an unblinded 
fashion.  Randomizati on codes for each enrolled patient will be provided by the research 
pharmacist.  The Committee will makes its recommendations by monitoring progress, data, 
outcomes, toxicity, safety and other confidential data, and may recommend stopping the clinical 
trial if an excessive number of serious adverse events are observed.  
 
DSMB -Committee  Members:  
1) CHAIRPERSON:  , Nephrology  and Hypertension  
2) STATISTICIAN:  , Biostatistics  
3) MEMBERS:  , General Internal Medicine and  , 
Community Internal Medicine  
 
9 Data  Handling  and Record  Keeping  
 
9.1 Confidentiality  
Information about study  subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the following:  
• What  protected  health  information  (PHI)  will be collected  from  subjects  in this study  
• Who  will have  access  to that information  and why 
• Who  will use or disclose  that information  
• The rights  of a research  subject  to revoke  their authorization  for use of their PHI. 
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of subject 
authorization.  For subjects that have revoked auth orization to collect or use PHI, attempts  
should be made to obtain permission to collect at least vital status (long term survival status that 
the subject is alive) at the end of their scheduled study period.  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  50 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 9.2 Source  Documents  
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source  documents.  Examples of  these orig inal documents, and data  records 
include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcriptions  certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved  
in the clinical trial.  
 
9.3 Case  Report  Forms  
The study case report form (CRF) is the primary data collection instrument for the study. Case 
reports  in the form  of completed  checklists  will be kept to ensure  inclusion/exclusion  criteria and 
review of adverse events/toxicity. All data requested on the CRF will be recorded in indelible 
pen. Pencils are not to be used.  Missing data will be explained. If a space on the CRF is left 
blank because the procedure was not done or the quest ion was not asked, “N/D” will be written. 
If the item is not applicable to the individual case, “N/A” will be written. All entries will be 
printed legibly in black ink. If any entry error has been made, to correct such an error, a single 
straight line will  be drawn through the incorrect entry and the correct data will be entered above 
it. All such changes  will be initialed  and dated.  Errors  will not  be erased  and “white -out” will not 
be used to correct errors. For clarification of illegible or uncertain ent ries, the clarification will  
be printed above the item, initialed, and dated. If the reason for the correction is not clear or 
needs additional explanation, details will be added related to the justification for the correction.  
 
Data  Management  
The data will be housed  in both hard copy  case report  forms  (CRFs)  and eCRFs  through  a system 
called Medidata RAVE.  
 
Data  Processing  
Source documents and CRFs and original consents will be stored in secured locations. All data 
will be entered into a password protected, limited access database. Individually -identifiable 
patient  history  and medical  record  information  will be stored  in a database  under  coded accession 
numbers. Clinical laboratory values will be stored in the electronic medical record system, 
requiring protected password access. These data are monitored regularly for access and a formal 
policy regarding protection of persona l privacy is in place. The key to identification of subjects 
will be maintained in a secure office environment under the direction of the principal 
investigators.  
 
Data  Security  and Confidentiality  
Source documents and CRFs and original consents will be st ored in secured locations. All data 
will be entered into a password protected, limited access database. Individually -identifiable 
patient  history  and medical  record  information  will be stored  in a database  under  coded  accession 
numbers. Clinical laboratory  values will be stored in the electronic medical record system, 
requiring protected password access. These data are monitored regularly for access and a formal 
policy  regarding  protection  of personal  privacy  is in place.  The key to identification  of subjects  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  51 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 will be maintained in a secure office environment under the direction of the principal 
investigators.  
 
Data  Quality  Assurance  
Manual and computerized quality checks will occur during data collection and analyses and any 
discrepancies will require Case Report Form (CRF) review and validation of correct data.  
 
Data  Clarification  Process  
Each  eCRF  contains  edit checks  and custom fun ctions  to ensure  the highest  possible  data quality. 
Only necessary eCRF’s are available for data entry to reduce the possibility of erroneous entry. 
After completion of data entry and resolving all outstanding queries, the database will be closed, 
and the data will be exported for statistical analysis.  
 
9.4 Records  Retention  
The investigator will maintain records and essential documents related to the conduct of the 
study. These will include subject case histories and regulatory documents. The sponsor - 
investig ator will retain the specified records and reports:  
1. As outlined in the Mayo Clinic Research Policy Manual –“Retention of and Access to 
Research Data Policy”  
• “2 years following the date a marketing application is approved for the drug for the  
indication for which it is being investigated” OR  
• “2 years  after the investigation  is discontinued  and FDA  is notified  if no application  is 
to be filed or if the applicati on has not been approved for such indication” OR  
• “Whichever  is longer.”  
 
10 Study  Monitoring,  Auditing,  and Inspecting  
 
10.1 Study  Monitoring  Plan  
This study will utilize a  Data and Safety Monitoring Board (DSMB) to provide a system for 
appropriate oversight and attention to the protection of human subjects and quality assurance. 
The DSMB will have the following monitoring activities: (1) Review of a pre -specified safety 
assessment after 6 subjects in each arm have completed safety follow -up period day 1; If the 
DSMB determines that it is safe to proceed the next dose will be administered and a safety 
assessment  will be performed  to determine  if it is safe to continue  to the highest  dosing  of 10ug;  
(2) prospective review of any issues related to the safety of subjects; and (3) regular review (i.e., 
twice yearly) of measures designed to protect the validity of the data and the integrity of the 
research study. With regard to  monitoring activity (2), safety issues will include the timely 
review of all SAEs (within 24 hours) and the regular review (every 3 months) of all AEs. With 
regard to monitoring activity 3, the DSMB will review with the principle investigator and lead 
study coordinator the methods in which data is collected, stored, and protected, including review 
of randomly selected subject case report and other forms. The DSMB will also identify when to 
terminate a subject’s participation by following prescribed individ ual stopping rules and when to 
terminate the study by following prescribed study stopping rules. Prescribed individual stopping 
rules  will include  the following:  (1) Any SAE  that precludes  further  participation  of the subject;  
(2) With respect to subjects that have not received study drug, any SAE related to the study drug 
that in the opinion  of the principle  investigator  or DSMB  places  subjects  at high risk of 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  52 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 experiencing the same SAE; (3) if in the opinion of the principle investigator, there is doubt that  
a subject, for any reason, can continue to fully participate in the study. Prescribed study stopping 
rules will include the following: (1) dose -limiting tox icities as defined elsewhere in this 
document in > 2 subjects for the lowest dose concentration of study drug. See also section 8.4, 
Stopping Rules . This will not preclude the analysis of pre -existing data.  
 
In addition to ongoing review of study progress by the Sponsor -Investigator, and delegated 
research staff, the key study source data, the study database and regulatory documents will be 
monitored on a periodic basis by the Mayo Clinic Office of Research Regulatory Support for the 
Mayo Clinic sites.  
 
Study monitoring is provided as a service for the sponsor -investigator to assist with compliance 
activities  and to assess protection of  research subjects and data  validity.  Monitoring may  include 
but is not limited to a Study Initiation Visit and periodic interim monitoring visits as the study 
progresses.  Written reports will be issued to the Sponsor -Investigator and Study Coordinator 
and should be provided to the IRB by Mayo Clinic study staff at the time of continuing IRB 
review.  
 
The Principle Investigat or will allocate adequate time for such monitoring activities, give access 
to all study -related documents and study related facilities (e.g. pharmacy, diagnostic laboratory, 
etc.) as needed, and provide adequate space to conduct monitoring inquiries.  
 
10.2 Audi ting and Inspecting  
The investigator will permit study -related monitoring, audits, and inspections by the IRB, the 
sponsor, and government regulatory agencies, of all study related documents (e.g. source 
documents, regulatory documents, data collection ins truments, study data etc.).  The investigator 
will ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, 
diagnostic laboratory, etc.).  
 
Participation as an investigator in this study implies acceptance of potential ins pection by 
government regulatory authorities and applicable compliance offices.  
 
11 Ethical Considerations  
This study  will be conducted  according  to United States government  regulations  and Institutional 
research policies and procedures.  
 
This protocol and an y amendments will be submitted to the Mayo Clinic Institutional Review 
Board (IRB), in agreement with local legal prescriptions, for formal approval of the study.  The 
decision of the Mayo Clinic IRB concerning the conduct of the study will be made in writi ng to 
the sponsor -investigator before commencement of this study.  
 
All subjects for this study will be provided a consent form describing this study and providing 
sufficient information for subjects to make an informed decision about their participation in this 
study.  This consent form will  be submitted  with the protocol for  review  and approval by  the IRB 
for the study.  The formal consent of a subject, using the Approved IRB consent form, will be 
obtained  before  that subject  undergoes  any study  procedure.  The consent  form  will be signed  by 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  53 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 the subjec t or the subject’s legally authorized representative, and the individual obtaining the 
informed consent.  
 
12 Study  Finances  
 
12.1 Funding  Source  
This study  will be financed  by Genome  Protection  Inc. 
 
12.2 Conflict  of Interest  
Any study team member who has a conflict of interest with this study (patent ownership, 
royalties, or financial gain greater than the minimum allowable by their institution, etc.) must 
have the conflict reviewed by a properly constituted Conflict of Intere st Committee with a 
Committee -sanctioned conflict management plan that has been reviewed and approved by the 
study sponsor -investigator prior to participation in this study.  
 
12.3 Subject  Stipends  or Payments  
 
Remuneration will consist of up to $600.00 if the subjects complete the entire study. Subjects 
will receive remuneration for each visit as follows:  
 
1. Visit  1: Screening  $100.00  
2. Visit  2: Baseline/Randomization  $75.00  
3. Visit  3: Follow -up Day 1 $75.00  
3. Visit  4: Follow -up Day 7 $25.00  
4. Visit  5: Monthly  Long -Term  Month  1 $75.00  
5. Visit  6: Monthly  Long -Term  Month  2 $75.00  
6. Visit  7: Monthly  Long -Term  Month  6 $75.00  
7. Visit  8: End of Study  Month  12 $100.00  
 
Completion of a study period means that the subject followed all study -related procedures for 
each day as described in the consent form. In addition, subjects will receive parking passes or  
taxi reimbursement or cost per mile traveled to the research cente r for the time involved with 
completing the study visits or travels to the research center for study visits. Subjects will be 
directed  where  to park in order  to receive  the parking  passes. For  subjects  who travel  greater  than 
50 miles to the research cente r subjects will be eligible to receive reimbursement for travel 
expenses including mileage at the current IRS mileage rate and parking.  In order to receive 
reimbursement, subjects will be required to provide a copy of the original receipts for those 
expens es. 
 
13 Publication  Plan 
It is the intention of the principle investigator to publish the results regarding the primary, 
secondary,  and exploratory  endpoints  of this study.  Criteria  set by the International  Committee  of 
Medical Journal Editors will be used to establish authorship. The primary responsibility for 
publication of the study results, including determination of authors and order of authorship, will 
be with the principle investigator of record. It is understoo d that the primary investigator of 
record  will work  in collaboration  with a designee  of the sponsor,  and all co-authors  to produce  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  54 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 manuscript(s) suitable for publication and with the approval of all authors. There will be 
agreement between th e principle investigator of record and the sponsor designee before any 
study -generated information can be used or passed on to a third party. All publications will refer 
to the ClinicalTrials.gov registration of the study and will adhere to any regulations  related to 
posting of results to ClinicalTrials.gov (e.g., within 12 months of final data collection for the 
primary outcome).  
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  55 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 14 References  
 
1. Goodwin  K, Viboud  C, Simonsen  L. Antibody  response  to influenza  vaccination  in the 
elderly: a quantitative review. Vaccine . 2006;24(8):1159 -1169. 
doi:10.1016/j.vaccine.2005.08.105  
2. Weinberger B, Herndler -Brandstetter D, Schwanninger A, Weiskopf D, Grubeck - 
Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect 
Dis. 2008;46(7):1078 -1084. doi:10.1086/529197  
3. Henry  C, Zheng N -Y, Huang  M, et al. Influenza Virus  Vaccination  Elicits  Poorly  Adapted 
B Cell Responses in Elderly Individuals. Cell Host Microbe . 2019;25(3):357 -366.e6. 
doi:10.1016/j.chom.2019.01.002  
4. Rolfes MA, Yousey -Hindes KM, Meek JI, Fry  AM, Chaves SS. Respiratory Viral Testing 
and Influenza Antiviral Prescriptions During Hospitalization for Acute Respiratory 
Illnesses. Open forum Infect Dis . 2016;3(1):ofv216. doi:10.1093/ofid/ofv216  
5. Burdelya LG, B rackett CM, Kojouharov B, et al. Central role of liver in anticancer and 
radioprotective activities of Toll -like receptor 5 agonist. Proc Natl Acad Sci U S A . 
2013;110(20):E1857 -66. doi:10.1073/pnas.1222805110  
6. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll -like receptor 5 has 
radioprotective activity in mouse and primate models. Science . 2008;320(5873):226 -230. 
doi:10.1126/science.1154986  
7. Yoon S, Kurnasov O, Natarajan V, et al. Structural basis of TLR5 -flagellin recognition 
and signali ng. Science . 2012;335(6070):859 -864. doi:10.1126/science.1215584  
8. Krivokrysenko VI, Shakhov AN, Singh VK, et al. Identification of granulocyte colony - 
stimulating factor and interleukin -6 as candidate biomarkers of CBLB502 efficacy as a 
medical radiation co untermeasure. J Pharmacol Exp Ther . 2012;343(2):497 -508. 
doi:10.1124/jpet.112.196071  
9. Vijay -Kumar M, Aitken JD, Sanders CJ, et al. Flagellin treatment protects against 
chemicals, bacteria, viruses, and radiation. J Immunol . 2008;180(12):8280 -8285. 
doi:10.40 49/jimmunol.180.12.8280  
10. Burdelya LG, Gleiberman AS, Toshkov I, et al. Toll -like receptor 5 agonist protects mice 
from dermatitis and oral mucositis caused by local radiation: implications for head -and- 
neck cancer radiotherapy. Int J Radiat Oncol Biol Phys . 2012;83(1):228 -234. 
doi:10.1016/j.ijrobp.2011.05.055  
11. Jones RM, Sloane VM, Wu H, et al. Flagellin administration protects gut mucosal tissue 
from irradiation -induced apoptosis via MKP -7 activity. Gut. 2011;60(5):648 -657. 
doi:10.1136/gut.2010.223891  
12. Kojouharov BM, Brackett CM, Veith JM, et al. Toll -like receptor -5 agonist Entolimod 
broadens the therapeutic window of 5 -fluorouracil by reducing its toxicity to normal 
tissues in mice. Oncotarget . 2014;5(3):802 -814. doi:10.18632/oncotarget.1773  
13. Krivokryse nko VI, Toshkov IA, Gleiberman AS, et al. The Toll -Like Receptor 5 Agonist 
Entolimod Mitigates Lethal Acute Radiation Syndrome in Non -Human Primates. PLoS 
One. 2015;10(9):e0135388. doi:10.1371/journal.pone.0135388  
14. Davies B, Morris T. Physiological paramete rs in laboratory animals and humans. Pharm 
Res. 1993;10(7):1093 -1095.  
15. Montecino -Rodriguez E, Berent -Maoz B, Dorshkind K. Causes, consequences, and 
reversal   of  immune   system   aging.   J  Clin  Invest .  2013;123(3):958 -965. 
Entolimod  (CBLB502)  Version  3.0 
18JUN2020  
Page  56 of 56 
R. Pignolo,  M.D.,  Ph.D.  CONFIDENTIAL   
 doi:10.1172/JCI64096  
16. Public  summary  of opinon  on ophan  designation  (EU/3/15/1607):  Entolimod  for the 
tratment  of acute  radiation  syndrome.  2016  Jan 11. European  Medicines  Agency. 
https:/ /www.ema.europa .eu/en/medicines/human/orp han-designations/eu3151607.  
Published 2016. Accessed July 9, 2019.  
17. Howell BA, Siler SQ, Shoda LKM, Yang Y, Woodhead JL, Watkins PB. A mechanistic 
model of drug -induced liver injury AIDS the interpretation of elevated liv er transaminase 
levels in a phase I clinical trial. CPT pharmacometrics Syst Pharmacol . 2014;3:e98. 
doi:10.1038/psp.2013.74  
18. Weber J, Gunn H, Yang J, et al. A phase I trial of intravenous interleukin -6 in patients  
with advanced cancer. J Immunother Emphasis  Tumor Immunol . 1994;15(4):292 -302. 
http://europepmc.org/abstract/MED/7520334.  
19. Roberts AW. G -CSF: a key regulator of neutrophil production, but that’s not all! Growth 
Factors . 2005;23(1):33 -41. doi:10.1080/08977190500055836  
20. Clark SC, Kamen R. The human hematopoietic colony -stimulating factors. Science . 
1987;236(4806):1229 -1237. doi:10.1126/science.3296190  
21. Dainiak N. Radiation response: Changing concepts and emergi ng paradigms. Exp 
Hematol . 2003;31(6):435 -436. 
22. Hawn TR, Verbon A, Lettinga KD, et al. A common dominant TLR5 stop codon 
polymorphism abolishes flagellin signaling and  is associated with susceptibility to 
legionnaires’ disease. J Exp Med . 2003;198(10):1563 -1572. doi:10.1084/jem.20031220  
23. Hawn TR, Wu H, Grossman JM, Hahn BH, Tsao BP, Aderem A. A stop codon 
polymorphism of Toll -like receptor 5 is associated with resistance to systemic lupus 
erythematosus. Proc Natl Acad Sci U S A . 2005;102(30):10593 -10597. 
doi:10.1073/pnas.0501165102  
24. Hawn TR, Wu H, Grossman JM, Hahn BH, Tsao BP, Aderem A. A stop codon 
polymorphism of Toll -like receptor 5 is associated with resistance to systemic lupus 
erythematosus. Proc Natl Acad Sci U S A . 2005;102(30):10593 -10597. 
doi:10.1073 /pnas.0501165102  
25. Bayat  M, Nabavizadeh  A, Kumar  V, et al. Automated  In Vivo  Sub-Hertz  Analysis  of 
Viscoelasticity (SAVE) for Evaluation of  Breast Lesions. IEEE Trans Biomed Eng . 
2018;65(10):2237 -2247. doi:10.1109/TBME.2017.2787679  